Mental Health Β· SCA case

Generalised Anxiety Disorder

NICE CG113 GAD-7 SCA-ready
GAD
Generalised Anxiety Disorder Β· Clinical Reasoning Framework v2
GP & SCA Β· NICE CG113 / CKS 2024
GAD-7 β‰₯10Moderate-severe GAD β€” active treatment
6 monthsMinimum duration for GAD diagnosis
2 weeksMandatory SSRI review after initiation
NHS Talking TherapiesFirst-line psychological therapy (self-referral)
SertralineFirst-line SSRI β€” NICE CG113 (2023)
PregabalinSecond-line only β€” after β‰₯2 SSRI/SNRI failures
≀2 weeksBenzodiazepines: maximum duration in anxiety
PHQ-9Comorbid depression: mandatory in ALL GAD
πŸ“‹ Clinical Stem β€” Generalised Anxiety Disorder Presentation
A patient presents with persistent, excessive, uncontrollable worry across multiple life domains β€” accompanied by physical symptoms β€” requiring systematic assessment to confirm GAD, exclude organic and other psychiatric causes, and initiate an evidence-based biopsychosocial management plan.
"Ms Patel, 34 years old, presents asking for 'something for her nerves.' She describes constant worrying that she cannot switch off β€” about her job, her health, her children, her finances β€” for at least the past 8 months. She wakes at 3 am with racing thoughts, cannot concentrate at work, feels tense and irritable most days, and has had several episodes of palpitations and chest tightness that led her to attend A&E twice, where she was told 'everything was fine.' She has started avoiding motorway driving and declining social invitations. She feels embarrassed and tells you she 'just needs to get a grip.' Her husband thinks she is making herself ill with worry."
GAD presentations vary enormously β€” from predominantly somatic (palpitations, headaches, GI symptoms) where the anxiety is concealed, to predominantly psychological with florid worry and avoidance. The SCA scenario may present as health anxiety, occupational stress, a request for benzodiazepines, or a patient convinced they have cardiac disease. The framework applies across all presentations β€” the key is to identify excessive, uncontrollable worry across multiple domains lasting at least 6 months.
Scenario A β€” Somatic presentation 45yo man, 6-month palpitations and chest tightness, multiple A&E attendances with normal cardiac investigations. Has not connected symptoms to anxiety. Needs the link made explicitly and empathetically with normal ECG as therapeutic reassurance.
Scenario B β€” Benzodiazepine request 52yo woman, known GAD, presents requesting diazepam "like before." Has been using intermittently for 3 years. Dependence risk must be addressed β€” cannot simply prescribe. Active management plan with SSRI and NHS Talking Therapies needed.
Scenario C β€” GAD with comorbid depression 38yo teacher, persistent worry 9 months, PHQ-9 score 14. Anhedonia, early morning wakening, low energy alongside anxiety. Comorbid depression changes management: SSRI first-line for both; 2-week suicide review mandatory.
Scenario D β€” Health anxiety 29yo, repeated medical consultations for cancer fear, multiple normal investigations, reassurance-seeking behaviour. GAD-7 8. Key: avoid over-investigation; address the anxiety, not the symptom; limited investigations used therapeutically.
Scenario E β€” Adolescent / young adult 17yo student, 7-month worry, school avoidance emerging, sleep disturbance. NICE CG113 pathway; CAMHS threshold; parental involvement; school liaison; CBT first-line before SSRI in under-18.
Key variables to adapt for: Duration (must be β‰₯6 months for GAD); GAD-7 score (severity and NICE step); comorbid depression (PHQ-9 mandatory); substance use (caffeine, alcohol, cannabis β€” all worsen anxiety); organic causes (hyperthyroidism, phaeochromocytoma, cardiac arrhythmia); benzodiazepine request; safeguarding context.
Steps:
1
Step 1
History Taking β€” Open Question First Β· Targeted Questions Β· ICE Β· Psychosocial Context
β–²collapse
The GAD history has four parallel objectives: characterise the worry (content, controllability, duration, pervasiveness), screen for physical anxiety symptoms that may be masking the diagnosis, exclude organic causes and comorbid conditions (particularly depression and substance misuse), and assess psychosocial context. The patient asking for "something for my nerves" may have GAD, panic disorder, social anxiety, PTSD, or an organic cause β€” the history is what distinguishes them.
πŸŽ“ Consultation opener β€” use existing information first
"I can see from your notes that you've been having a really difficult time with your nerves lately β€” I'd love to hear about it in your own words. What's it been like for you?"
The phrase "in your own words" gives permission to describe the experience rather than a symptom list. Many patients with anxiety have rehearsed a somatic narrative (chest pain, racing heart) and the open question creates space for the emotional content to emerge. Re-asking documented facts wastes time and loses Global Skills marks.
1A β€” Start with an open question: let the patient lead, then move to targeted questions
Question to askWhy it matters clinicallyChanges what?
🟒 OPEN QUESTION β€” always start here"Tell me about the worry β€” what's been going on for you?" Anxiety is a subjective experience β€” the patient's own framing reveals more than any checklist. Phrases like "I can't stop my brain," "I'm always waiting for something bad to happen," or "even good news makes me anxious" are diagnostically specific for GAD. The content of the worry and its pervasiveness across domains emerge naturally with space.Scores: Global Skills (patient-centredness), Relating to Others (ICE foundation), Tasks (agenda setting). DDxPsychosocialRx plan
Characterise the worry β€” content and pervasiveness"What do you find yourself worrying about most? Is it one particular thing, or does the worry jump between many different topics?" GAD is distinguished by worry that is excessive, persistent, and multi-domain β€” work, relationships, health, finances, world events, minor daily matters. Worry focused on a single domain (contamination, social situations, trauma-related triggers) suggests OCD, social anxiety disorder, or PTSD respectively.Multi-domain pervasive worry is the diagnostic hallmark of GAD and distinguishes it from other anxiety disorders. DDxRx
Controllability β€” the GAD discriminator"When you start worrying, can you stop it? Or does the worry just run on regardless of what you try?" Uncontrollability of worry is the defining feature that separates pathological anxiety from normal adaptive worry. Patients with GAD cannot "switch off" despite distraction, exercise, or reassurance-seeking. This directly maps to GAD-7 item 2 and is the most specific discriminator in the history.If worry is controllable and context-limited, reconsider GAD β€” adjustment disorder or normal stress response is more likely. DDx
Duration β€” the 6-month diagnostic criterion"How long has the worrying been like this? Was there a time when you felt different β€” when it wasn't this constant?" NICE CG113 and DSM-5 both require symptoms for at least 6 months to diagnose GAD. Shorter duration with a clear precipitant is more consistent with adjustment disorder. Patients often present after months or years of untreated GAD β€” they have normalised their experience. Asking "was there a time when it was different?" can reveal much longer duration than first reported.Duration <6 months β†’ adjustment disorder or generalised anxiety; treat but do not label as GAD. DDxRx
Physical symptoms of anxiety"Do you get physical symptoms with the worry β€” heart racing, chest tightness, breathlessness, shaking, sweating, headaches, stomach problems?" Physical anxiety symptoms are experienced by the majority of patients with GAD and are often the primary presenting complaint β€” the anxiety connection is not made by the patient. These symptoms generate extensive unnecessary medical investigations. Naming them and linking them to anxiety is both diagnostic and therapeutic.Physical symptoms without identified organic cause in a patient with GAD β†’ attribute to anxiety; avoid further investigation that reinforces illness focus. DDxInvRx
Sleep disturbance"How is your sleep? Do you have trouble getting off, or do you wake in the night with your mind racing?" Sleep disturbance β€” particularly difficulty initiating sleep due to rumination, or waking at 3 am with racing thoughts β€” is both a diagnostic criterion for GAD and a major perpetuating factor. The pattern of 3 am wakening with intrusive worry is almost pathognomonic of anxiety-related sleep disruption and helps distinguish from early morning wakening of depression.Pattern and timing of sleep disturbance helps distinguish GAD from depression and guides treatment. DDxRx
Avoidance behaviour"Are there things you've stopped doing because of the worry β€” places you avoid, situations you turn down?" Avoidance is both a marker of severity and a major maintaining factor in GAD. Patients avoid situations perceived as anxiety-provoking (motorway driving, social gatherings, medical appointments). Avoidance provides short-term relief but long-term maintenance of anxiety by preventing habituation. Identifying specific avoidance behaviours also guides CBT targets.Extensive avoidance indicates severe GAD requiring active treatment; determines CBT priority targets. DDxRx
Screen for comorbid depression β€” mandatory in all anxiety"Underneath all the worry, how has your mood been? Have you lost interest in things you used to enjoy? Any thoughts of harming yourself?" Depression and GAD are the most commonly comorbid psychiatric conditions in primary care β€” 50–70% of GAD patients have comorbid depression. PHQ-9 is mandatory in all patients presenting with anxiety. Comorbidity dramatically worsens prognosis and changes treatment planning. Suicidal ideation must be assessed when depression is identified.Comorbid depression changes SSRI selection, monitoring frequency, and safety planning requirements. DDxRxRisk
Substance use β€” caffeine, alcohol, cannabis"How much caffeine do you have per day β€” coffee, tea, energy drinks? What about alcohol β€” how many units a week? Any recreational drugs?" Caffeine is a direct anxiogenic β€” even 200mg (2 cups of coffee) significantly worsens GAD symptoms via adenosine receptor antagonism. Alcohol causes initial anxiolysis followed by rebound anxiety β€” a common maintenance cycle. Cannabis causes acute anxiety and can precipitate GAD. All three must be addressed before or alongside pharmacological treatment.An anxious patient who drinks 4 units nightly will have a very limited SSRI response if alcohol is not addressed. DDxRx
Panic attacks β€” distinguish GAD from panic disorder"Do you ever get sudden overwhelming waves of fear or anxiety β€” like a surge β€” that come on very quickly and peak within minutes?" Panic attacks are discrete episodes of acute intense fear with β‰₯4 somatic symptoms, peaking within 10 minutes. They can occur in GAD, but if they are the primary problem β€” unexpected, with anticipatory worry about future attacks and avoidance β€” the diagnosis is panic disorder, requiring a different CBT approach (interoceptive exposure).Panic disorder may need specialist NHS Talking Therapies input; GAD can often be managed at step 2–3 in primary care. DDxRxReferral
Thyroid and cardiovascular symptom screen"Any changes in your weight, heat or cold intolerance, palpitations at rest, or episodes of very high blood pressure?" Hyperthyroidism classically mimics GAD β€” anxiety, palpitations, tremor, weight loss, heat intolerance. Phaeochromocytoma causes episodic hypertension, palpitations, and diaphoresis. These must be excluded by examination and investigation, particularly in new-onset anxiety in an older adult without an obvious precipitant.TSH is mandatory in all new anxiety presentations. Thyroid disease is both a mimic and a comorbid condition. DDxInv
Functional impairment"How much is this affecting your day-to-day life β€” your work, relationships, things you do at home?" GAD by definition causes clinically significant distress or functional impairment. The degree of impairment determines treatment intensity (NICE step 2 vs. step 3) and urgency. Significant occupational impairment may require a fit note. Social isolation and relationship strain perpetuate anxiety and must be addressed in the management plan.Functional impairment score determines NICE stepped care level and justifies medication initiation if severe. DDxRxReferral
1B β€” Red flags: must not miss Β· must ask Β· must act
🚨

Red Flags β€” act before continuing history

Red flagWhy dangerousAction
Active suicidal ideation with plan or intentGAD with comorbid depression carries significant suicide risk. PHQ-9 β‰₯15 with positive item 9 and specificity of plan requires same-day crisis assessment.Same-day CRHT / 136 / A&E
New-onset anxiety in older adult (>50) without psychological precipitantOrganic suspicion mandatory: hyperthyroidism, cardiac arrhythmia, phaeochromocytoma, early dementia, alcohol withdrawal. GAD rarely presents de novo after 50 without a precipitant.Urgent bloods + ECG within 1 week
Palpitations + syncope or near-syncope + anxietyCardiac arrhythmia (AF, SVT, WPW, prolonged QTc) causing palpitations can trigger anxiety β€” the anxiety is a response, not the cause. Syncope with palpitations must have cardiac cause excluded before attributing to anxiety.ECG same day + cardiology
Episodic severe hypertension + sweating + headache + palpitationsPhaeochromocytoma presents with paroxysmal episodes of severe hypertension, diaphoresis, headache, and palpitations β€” frequently misattributed to anxiety. Missing it is catastrophic: hypertensive crisis, stroke, cardiac arrest.Urgent endocrinology + 24h urinary catecholamines
Rapid weight loss + anxiety + heat intolerance + tremorHyperthyroidism or thyroid storm can present as severe anxiety with weight loss, heat intolerance, and palpitations. TSH mandatory; if very suppressed and systemically unwell β†’ urgent endocrinology.Urgent TSH + free T4 + endocrinology if severe
Anxiety + focal neurological symptoms (headache, weakness, vision change)CNS pathology (space-occupying lesion, encephalitis, temporal lobe epilepsy) can present with anxiety and personality change as early symptoms. New anxiety with focal neurology requires urgent imaging.Urgent CT/MRI head + neurology referral
Severe self-neglect or inability to care for dependants due to anxietyGAD so severe the patient cannot perform ADLs or care for dependent children constitutes a functional emergency requiring same-day psychiatric assessment and social services involvement.Same-day psychiatric assessment + safeguarding
πŸ›‘οΈ

Safeguarding Considerations β€” Consider in Every Consultation

Anxiety is both a consequence of, and a risk factor for, harm. GAD may be sustained by ongoing domestic abuse, coercive control, unsafe housing, or workplace harassment. Equally, a parent with severe untreated GAD may be unable to meet the needs of dependent children or adults in their care.
🏠 Domestic Abuse / Coercive Control
  • Chronic anxiety maintained by ongoing threat in the home environment
  • Partner insists on attending or speaks on behalf of the patient
  • Anxiety significantly worse when home or relationship safety is asked about
  • History of repeated anxiety consultations without improvement β€” consider ongoing threat
  • Use the DASH risk assessment if domestic abuse is suspected
πŸ‘Ά Children in the Household
  • Parent with severe GAD may be unable to meet children's emotional and physical needs
  • Parental anxiety transmitted to children β€” anxious parenting amplifies childhood anxiety
  • Review whether children are attending school and developing appropriately
  • Involve health visitor or school nurse if concern about parenting capacity
πŸ‘΄ Carer and Elder Safeguarding
  • Carer anxiety about the person they care for β€” burnout and risk of harm to dependant
  • Older adult with anxiety and cognitive decline β€” capacity assessment may be needed
  • Financial abuse anxiety β€” patient coerced into financial decisions causing significant anxiety
  • Isolated older adult with anxiety and no social support β€” review safety at home
⚠ Self-Harm and Suicide Risk
  • GAD with comorbid depression β€” assess suicidal ideation at every appointment
  • Anxiety with alcohol or substance use β€” increased suicide risk; impaired inhibition
  • Self-medication with benzodiazepines or alcohol β€” escalating misuse pattern
  • Social isolation + hopelessness + GAD = significant suicide risk constellation
If a safeguarding concern is identified: See the patient alone first. Use the practice safeguarding lead. For domestic abuse: DASH risk assessment; MASH or IDVA referral. For children at risk: MASH referral same day. For adults at risk: adult safeguarding referral. Document reasoning carefully. Do not delay safeguarding action to continue treating the anxiety.
1C β€” PMH Β· FH Β· Drug history Β· Social history: management impact
🧬 PMH / FH β€” changes management
FactorWhy it mattersManagement impact
Previous depression or anxiety disorderStrongest predictor of recurrence; previous treatment response guides current choiceReview what worked before; if SSRI was effective, restart same agent at same dose
Thyroid diseaseBoth hypo- and hyperthyroidism worsen or mimic anxiety; hypothyroidism causes anxiety in some patientsTSH mandatory; treat thyroid disorder before or alongside anxiolytic treatment
Cardiac disease (arrhythmias, IHD, HF)Palpitations from arrhythmia trigger anxiety; SSRIs safe in most cardiac diseaseECG; sertraline preferred SSRI in cardiac disease; avoid TCAs; cardiology if arrhythmia
Family history of anxiety or depressionStrong genetic component to GAD (heritability ~30%); normalises the conditionGenetic predisposition framing reduces self-blame; supports medication acceptance
Chronic pain (fibromyalgia, IBS, chronic fatigue)GAD highly comorbid with chronic pain; anxiety amplifies pain perceptionSNRIs (duloxetine, venlafaxine) address both anxiety and pain; CBT for dual pathway
ADHD (diagnosed or suspected)Anxiety common in ADHD; stimulants can worsen anxiety; ADHD misattributed as anxietyScreen for ADHD; coordinate with ADHD team; atomoxetine may help both
Alcohol use disorder or benzodiazepine dependenceBoth worsen GAD long-term; alcohol causes rebound anxiety; benzos cause dependenceTreat dependence before or alongside GAD; structured reduction; SSRI once detoxified
EpilepsySome antiepileptics (pregabalin) have dual use; drug interactions importantLiaise with neurology before adding pregabalin; SSRIs generally safe
πŸ’Š Drug history Β· Social history β€” clinical impact
FactorWhy it mattersManagement impact
Caffeine intake (coffee, tea, energy drinks, cola)Direct anxiogenic; 300–400mg/day significantly worsens GAD symptoms; often overlookedQuantify intake; advise reduction; switch to decaf; expect anxiety improvement in 2–4 weeks
Current benzodiazepines or Z-drugsShort-term anxiolysis but long-term worsening; dependence risk; rebound anxietyDo not prescribe new benzos for chronic GAD; if already prescribed, structured withdrawal plan; SSRI as alternative
Beta-blockers (propranolol)Reduce peripheral anxiety symptoms but not central worry; not first-line for GADCan be continued if symptom benefit; not substitute for CBT or SSRI; avoid in asthma, COPD
Corticosteroids (oral or inhaled at high dose)Exogenous steroids cause anxiety, insomnia, and mood disturbance directlyReview steroid indication and dose; anxiety may resolve on dose reduction
Occupational stress and working conditionsWorkplace is the most common precipitant of GAD; job insecurity, bullying, overwork are major triggersOccupational health referral; fit note if impaired; workplace adjustments under Equality Act; EAP referral
Financial insecurity, housing instabilityObjective life stressors maintain anxiety biologically; treating without addressing stressor limits effectivenessSocial prescribing; Citizens Advice; debt counselling; housing support; acknowledge stressor validity
Cannabis useCannabis causes acute anxiety and can precipitate anxiety disorders; used by many patients to self-medicate β€” worsens long-termAUDIT/ASSIST screen; motivational interviewing; drug and alcohol service if dependent; SSRI more effective once use reduced
Relationship or social isolationSocial support is the strongest protective factor against anxiety; isolation is the strongest maintaining factorSocial prescribing; community referral; group CBT; MIND peer support
1D β€” ICE: Ideas Β· Concerns Β· Expectations β€” in every consultation, not just SCA
πŸ’‘ Why ICE matters in GAD β€” not a tick-box exercise

Patients with GAD present with a profound mismatch between what they fear (serious physical disease) and what is actually happening (anxiety). The patient with palpitations may be seeking reassurance about heart disease, not a mental health diagnosis. Without exploring their ideas and concerns, the GP cannot bridge this gap. A patient who believes medication is "addictive" will not adhere to an SSRI prescription. ICE in GAD determines whether treatment is accepted and used.

πŸ’­ Ideas
"What do you think is going on? When the palpitations happen and the worry kicks in, what goes through your mind about what might be causing it?"
Many patients with GAD have a specific disease model β€” they believe they have a heart condition, cancer, or neurological disease. This drives reassurance-seeking and healthcare utilisation. Until you know the patient's model, you cannot correct it. Providing an anxiety diagnosis to a patient convinced they have heart disease without addressing that belief first will result in the diagnosis being rejected.
😟 Concerns
"What is your biggest fear about what's going on β€” is there something specific you've been worried this might be?"
The most common hidden concern in anxiety presentations is a feared serious physical diagnosis β€” most frequently cardiac disease or cancer. Secondary concerns include fear of "losing control," becoming dependent on medication, or being labelled as mentally ill. Each requires a specific, targeted response. Vague reassurance does not address the specific fear and leaves the patient unsatisfied.
🎯 Expectations
"What were you hoping we could do today? Is there something specific you were looking for from this appointment?"
Common expectations in GAD: "something to calm me down" (often meaning benzodiazepines), "a referral to a specialist," "more tests," or "just to feel heard." Each must be acknowledged and negotiated. The expectation for benzodiazepines is understandable but requires sensitive redirection. The expectation for tests may be partially met (TSH, ECG) while explaining that further investigation is unhelpful.
1E β€” Psychosocial context: the person behind the anxiety
πŸ«‚ GAD Is Almost Never Just Biological β€” The Psychosocial Web That Maintains Anxiety

GAD is maintained by a complex interaction of biological predisposition, cognitive patterns (intolerance of uncertainty, catastrophising, worry as a coping strategy), behavioural patterns (avoidance, reassurance-seeking), and environmental stressors. Treatment addressing only the biological component (medication) without the psychological and social components produces limited, non-durable improvement. NICE mandates a stepped care biopsychosocial approach precisely because single-modality treatment is insufficient.

🧠 Intolerance of Uncertainty

The core cognitive vulnerability in GAD is intolerance of uncertainty β€” the belief that uncertain situations are inherently threatening and must be resolved. Patients with GAD are hypervigilant to ambiguity and experience uncertainty as intolerable. This drives worry as a strategy to mentally "solve" uncertain situations in advance.

"When something is uncertain β€” when you don't know how something will turn out β€” how does that feel? Can you tolerate not knowing, or does it feel unbearable?"

Intolerance of uncertainty is directly addressed in CBT for GAD. Identifying it frames CBT as treating the root cause, not just symptoms.

πŸ”₯ Chronic Stress and Life Circumstances

Ongoing objective stressors β€” financial precarity, caring responsibilities, job insecurity, relationship conflict, housing instability β€” maintain anxiety biologically through sustained HPA axis activation. Treating anxiety without addressing these factors is like bailing out a leaking boat.

"When you think about where the worry comes from β€” what are the main things in your life right now that feel most uncertain or threatening?"

Address objective stressors: Citizens Advice, social prescribing, occupational health. Acknowledging their validity in the consultation itself is therapeutic.

πŸ’” Childhood and Early Adversity

Adverse childhood experiences significantly increase the risk of adult GAD via epigenetic programming of the HPA axis and hypervigilance to threat. A history of early adversity may indicate that standard CBT is insufficient and trauma-focused therapy is needed.

"Sometimes anxiety in adulthood is connected to experiences people have had much earlier in their lives. Is that something that feels relevant to you at all?"

If significant early adversity: EMDR or trauma-focused CBT may be more appropriate than standard CBT; NHS Talking Therapies can provide this.

🧭 Beliefs About Worry

Patients with GAD commonly hold positive metacognitive beliefs about worry β€” "worrying means I'm responsible," "if I worry about it, I'll be prepared," or "worrying keeps the people I love safe." These beliefs make worry feel purposeful and difficult to relinquish. CBT for GAD directly addresses these metacognitive beliefs.

"When you worry, does it ever feel like the worry is doing something useful β€” like it's keeping you prepared, or keeping bad things from happening?"

Identifying positive worry beliefs helps explain why the patient hasn't "just stopped" and frames CBT as teaching a different relationship with uncertainty.

πŸ˜“ Shame and Stigma

Patients with GAD often carry profound shame β€” they believe they should be able to control their own minds, and that anxiety reflects weakness or failure. This shame delays help-seeking by years and causes patients to resist psychiatric diagnoses and psychological treatments.

"Sometimes people feel a lot of shame about anxiety β€” like they should just be able to pull themselves together. Has that been part of your experience?"

Psychoeducation β€” "anxiety is a biological survival system that's become overtuned, not a personality flaw" β€” reduces shame and improves treatment engagement.

πŸ”„ Reassurance-Seeking

Excessive reassurance-seeking β€” from GPs, family members, or online β€” provides temporary relief but maintains anxiety by reinforcing the belief that reassurance is necessary for safety. It is a form of behavioural avoidance that prevents natural habituation.

"When you feel anxious, do you find yourself checking things, asking people to reassure you, or going online to look things up? Does that help in the moment but the worry comes back quickly?"

Gently limiting reassurance-seeking in primary care β€” agreeing a maximum number of consultations per month β€” is clinically beneficial, not dismissive.

πŸŽ“ SCA Checkpoint β€” Step 1TasksRelating to OthersGlobal Skills
Key phrases that score
"Tell me about the worry β€” what's it been like for you in your own words?"
"When the worry comes, can you choose to stop it, or does it just run on regardless of what you try?"
"Underneath all the anxiety, how has your mood been? Any thoughts of harming yourself?"
"Is there anything specific you've been worried this might be β€” anything you were hoping I could rule out today?"
Deductions (examiner flags)
  • Not asking about suicidal ideation in a patient with GAD and comorbid low mood
  • Not distinguishing GAD from panic disorder (no panic attack question)
  • Missing substance use (caffeine, alcohol, cannabis) as anxiety-maintaining factors
  • Not using GAD-7 as a validated screening tool
  • Not exploring whether the patient understands the anxiety diagnosis (ICE missed)
  • Offering benzodiazepines without addressing the risk of dependence
πŸ”΄ Red β€” failing
No GAD-7; no suicide screen; no distinction of GAD from panic/OCD/PTSD; launches into medication without ICE; offers benzodiazepines without discussion; ignores substance use.
🟠 Amber β€” borderline
GAD-7 mentioned but not used; mood screen verbal without PHQ-9; ICE partially explored; substance use asked but not addressed; panic attack distinction asked but not interpreted correctly.
🟒 Green β€” passing
GAD-7 and PHQ-9 both used; uncontrollability of worry specifically asked; panic attack distinction made; suicidal ideation screened; substance use reviewed; ICE fully explored; organic causes considered; psychosocial context assessed; duration confirmed β‰₯6 months.
2
Step 2
Triage Engine β€” Emergency Β· Urgent Β· Routine
β–²collapse
The vast majority of GAD presentations are suitable for routine stepped care management in primary care. However, a small number require urgent or emergency action. The two highest-risk scenarios are: active suicidal ideation with comorbid depression, and organic pathology (cardiac arrhythmia, hyperthyroidism, phaeochromocytoma) masquerading as GAD. Both must be systematically excluded at every new presentation.
πŸ”΄ Emergency

Same-Day Crisis / Hospital

Act immediately
  • Active suicidal ideation with plan or intentPHQ-9 item 9 positive with specificity β†’ same-day CRHT / 136 / A&E mental health liaison
  • Suspected phaeochromocytoma with hypertensive crisis (BP >180/120 + headache + diaphoresis)Hypertensive emergency β†’ 999; IV labetalol; endocrinology
  • Arrhythmia with haemodynamic compromise (syncope, severe tachycardia, hypotension)Cardiac emergency β†’ 999; ECG; cardiology
  • Acute psychosis presenting with anxiety featuresAnxiety + formal thought disorder + bizarre beliefs β†’ same-day mental health crisis team
  • Severe self-neglect or inability to care for dependantsGAD so severe patient cannot function β†’ same-day psychiatric assessment + social services
🟠 Urgent

Same-Day / 1–2 Week Assessment

Urgent investigation / referral
  • Suicidal ideation without immediate plan β€” PHQ-9 β‰₯15 with ideationCRHT contact same day; do not leave patient without safety plan
  • New-onset anxiety in patient >50 without psychological precipitantUrgent bloods (TSH, FBC, calcium, glucose); ECG; exclude organic cause within 1 week
  • Palpitations + syncope + anxietyECG same day; 24h Holter; cardiology within 2 weeks if arrhythmia found
  • GAD with benzodiazepine dependence requiring supervised withdrawalStructured diazepam withdrawal plan; weekly GP review; drug and alcohol service if complex
  • GAD with severe comorbid depression (PHQ-9 β‰₯15) β€” not imminently suicidalSSRI within days; NHS Talking Therapies urgent pathway; 2-week mandatory review; suicide safety net
🟒 Routine

Stepped Care β€” Primary Care

NICE stepped care pathway
  • GAD-7 5–9 (mild) β€” first presentationStep 2: psychoeducation + self-help + lifestyle + NHS Talking Therapies referral (low intensity)
  • GAD-7 β‰₯10 (moderate-severe) without red flagsStep 3: SSRI (sertraline 50mg) + high-intensity CBT via NHS Talking Therapies; 2-week review mandatory
  • GAD not responding to Step 3 after adequate trialStep 4: consider SNRI, pregabalin (specialist), or CMHT referral
  • GAD with comorbid mild depression (PHQ-9 <15)SSRI addresses both; NHS Talking Therapies; monthly review; PHQ-9 monitoring
πŸŽ“ SCA Checkpoint β€” Step 2TasksGlobal Skills
Triage phrases that score
"Before we talk about treatment, I want to check a few things β€” the mood questionnaire helps me make sure we're not missing anything that needs more urgent attention."
"I'm reassured this isn't something that needs emergency attention today β€” but I do want to run one or two tests to make absolutely sure there isn't a physical cause for some of these symptoms."
"Given the PHQ-9 score, I want to make sure we have a plan if things feel very dark β€” I want to check in with you on that specifically."
Triage deductions
  • Prescribing SSRI and booking 6-week follow-up without a 2-week safety review
  • Not excluding organic cause (TSH, ECG) in patient with palpitations and new-onset anxiety
  • Offering benzodiazepine as primary treatment for GAD without dependence discussion
  • Sending home patient with active suicidal ideation and a prescription alone
πŸ”΄ Red
SSRI without 2-week review; no organic exclusion; benzodiazepine for chronic GAD; active suicidal ideation not acted on; no triage distinction between mild and moderate-severe GAD.
🟠 Amber
Correct triage category but management plan inconsistent with severity; 2-week review mentioned but not arranged; organic exclusion incomplete; suicide risk assessed but safety net vague.
🟒 Green
GAD-7 severity matched to correct NICE step; organic exclusion planned; 2-week SSRI review explicitly arranged; suicide safety plan given if PHQ-9 positive; NHS Talking Therapies pathway explained; benzodiazepine risk addressed proactively.
3
Step 3
Do I Need This Examination?
β–²collapse
GAD is primarily a psychological diagnosis, but physical examination serves two critical functions: excluding organic pathology that can mimic or worsen anxiety (thyroid disease, cardiac arrhythmia, phaeochromocytoma), and providing a therapeutic experience β€” the normal examination finding, communicated clearly, is a powerful tool for addressing health anxiety and somatisation. Never omit the examination; always communicate what you found and what it means.
ExaminationWhy it mattersWhat finding changes managementChanges management?
Pulse β€” rate, rhythm, characterTachycardia may indicate anxiety, hyperthyroidism, phaeochromocytoma, or arrhythmia. Irregular pulse β†’ ECG for AF. Resting tachycardia >100 bpm β†’ investigate before attributing to anxiety alone.Pulse assessment takes 30 seconds and may change the entire management pathway.Irregular pulse β†’ ECG + cardiology; resting tachycardia >100 β†’ TSH + ECG; normal pulse β†’ document and use therapeutically for reassuranceYES β€” investigation pathway
Blood pressure β€” sitting and standingHypertension associated with anxiety. Episodic hypertension raises phaeochromocytoma. BP measurement essential at baseline before starting SSRIs.Document baseline BP before commencing any anxiolytic medication.Episodic marked hypertension (>180/120) + palpitations + headache β†’ 24h urinary catecholamines; sustained hypertension β†’ address alongside anxietyYES β€” investigation + safety
Thyroid examination β€” goitre, eye signs, tremor, reflexesHyperthyroidism: fine tremor, lid lag, proptosis, warm moist skin, diffuse goitre, brisk reflexes. These signs direct investigation and change management entirely.Thyroid examination should be routine in all new anxiety presentations with somatic symptoms.Signs of hyperthyroidism β†’ urgent TSH + free T4 + endocrinology; goitre β†’ USS thyroid + TFTsYES β€” investigation pathway
Cardiovascular β€” heart sounds, JVP, peripheral oedemaMitral valve prolapse associated with palpitations. Heart failure causes dyspnoea misattributed to anxiety. A clear cardiac examination with normal heart sounds provides therapeutic reassurance to a health-anxious patient.Auscultation findings communicated clearly to the patient after examination provide immediate therapeutic benefit.Murmur + palpitations β†’ echo referral; signs of HF β†’ BNP + echo; normal exam β†’ communicate explicitly as reassuranceYES β€” therapeutic reassurance
Mental state examination (MSE)Note affect, thought content (ruminative vs. paranoid), thought form (coherent vs. disorganised), speech rate, insight, concentration. Formal thought disorder or paranoid ideation suggest psychosis, not GAD. Psychomotor retardation suggests comorbid severe depression.MSE distinguishes GAD from comorbid depression, psychosis, and PTSD β€” all requiring different management.Psychomotor retardation + flat affect β†’ severe depression; paranoid ideation β†’ crisis team; PTSD hypervigilance + re-experiencing β†’ EMDR pathwayYES β€” diagnosis and pathway
Respiratory examination (if dyspnoea prominent)Asthma is the most common respiratory condition to mimic anxiety (and be comorbid with it). Peak flow measurement in a patient with breathlessness helps distinguish anxiety-related hyperventilation from bronchospasm.Normal respiratory examination supports functional diagnosis in a patient with dyspnoea attributed to anxiety.Wheeze + breathlessness β†’ asthma screen; normal examination + hyperventilation pattern β†’ anxiety explanation of respiratory symptomsContext β€” based on symptoms
Weight and BMIUnexplained weight loss + anxiety β†’ hyperthyroidism, malignancy, depression. Obesity + anxiety β€” sleep apnoea may contribute via nocturnal hypoxia. BMI relevant before prescribing SSRIs (weight gain is a side effect).Weight and BMI contextualise the anxiety and identify contributing comorbidities.Weight loss >5% β†’ investigate organic cause; obesity + snoring β†’ STOP-BANG for OSA; document before SSRI initiationYES β€” investigation direction
Abdominal examination (if GI symptoms prominent)IBS is highly comorbid with GAD. Abdominal pain and bloating in an anxious patient warrant examination to exclude organic pathology before attributing to anxiety. Normal abdominal examination provides reassurance.Normal abdominal examination provides reassurance and supports functional diagnosis in a patient with GI anxiety symptoms.Organomegaly or mass β†’ urgent investigation; normal examination β†’ reassure; IBS features β†’ low-FODMAP trial + NHS Talking Therapies referralContext β€” if GI symptoms
πŸŽ“ SCA Checkpoint β€” Step 3TasksRelating to OthersGlobal Skills
Examination communication that scores
"I'd like to do a quick check β€” your pulse, blood pressure, and a look at your neck for the thyroid, and I'll listen to your heart. I want to be thorough and also to give you concrete reassurance."
"Your heart is completely regular, your pulse is normal, and your blood pressure is fine. There's no sign of thyroid disease. That's genuinely reassuring β€” these symptoms are most likely being driven by the anxiety, not a physical problem."
"Your examination is normal β€” which means I can confidently say this is not your heart or your thyroid causing these sensations."
Examination deductions
  • No examination at all β€” even in a "psychological" presentation
  • Examining but not communicating findings to the patient
  • Missing thyroid examination in a patient with palpitations, tremor, and weight loss
  • Not checking pulse and BP before prescribing an SSRI
πŸ”΄ Red
No physical examination; misses thyroid examination in somatic presentation; does not communicate findings; prescribes SSRI without baseline BP or pulse documented.
🟠 Amber
Examination performed but findings not communicated; thyroid examination omitted in patient with palpitations; examination results not used therapeutically.
🟒 Green
Targeted examination with rationale explained; findings communicated clearly; normal findings used explicitly as therapeutic reassurance; abnormal findings trigger appropriate investigation; MSE documented.
4
Step 4
Do I Need This Investigation?
β–²collapse
GAD is a clinical diagnosis based on symptoms and duration β€” not a diagnosis of exclusion requiring extensive investigation. The strategy is targeted: exclude the most common organic mimics (thyroid disease, cardiac arrhythmia, hypoglycaemia), screen for comorbid depression (PHQ-9), and quantify anxiety severity (GAD-7). Over-investigation reinforces health anxiety, delays diagnosis, and increases healthcare costs without benefit. In patients with health anxiety, every normal investigation temporarily reduces anxiety but ultimately worsens the condition through the reassurance-seeking cycle.
InvestigationClinical question it answersWhat result changes management?
GAD-7 (Generalised Anxiety Disorder 7-item scale)Validated, NICE-recommended severity tool for GAD. Scores: 5–9 mild; 10–14 moderate; 15–21 severe. Guides treatment intensity, NHS Talking Therapies step, and monitoring. Mandatory at first presentation and every review.GAD-7 5–9 β†’ Step 2 (self-help, NHS Talking Therapies low-intensity); GAD-7 β‰₯10 β†’ Step 3 (CBT + SSRI); GAD-7 β‰₯15 β†’ Step 4 consideration; serial GAD-7 tracks treatment response (target β‰₯50% reduction)
PHQ-9 (Patient Health Questionnaire-9)Comorbid depression occurs in 50–70% of GAD patients β€” mandatory in every presentation. PHQ-9 β‰₯10 changes SSRI urgency, monitoring frequency, and suicide risk assessment. Item 9 (suicidal ideation) must always be reviewed.PHQ-9 β‰₯10 β†’ SSRI first-line (treats both), NHS Talking Therapies referral, 2-week review, suicide safety-net; PHQ-9 item 9 positive β†’ crisis assessment same day
TSH (Thyroid stimulating hormone)Mandatory in all new anxiety presentations. Hyperthyroidism is the most important organic mimic of GAD β€” anxiety, palpitations, insomnia, tremor, weight loss. Normal TSH excludes thyroid disease and supports the anxiety diagnosis.TSH <0.1 mU/L β†’ urgent endocrinology + propranolol for symptoms; TSH >10 β†’ treat hypothyroidism; may partially or fully resolve anxiety
ECG (12-lead)Exclude arrhythmia (AF, SVT, WPW, prolonged QTc). Indicated when: palpitations are prominent, palpitations + syncope, patient >50 with new anxiety and palpitations, or before prescribing medications that prolong QTc. Normal ECG provides powerful therapeutic reassurance.AF or flutter β†’ rate control + anticoagulation assessment; WPW β†’ urgent cardiology; prolonged QTc (>500ms) β†’ urgent cardiology; normal ECG β†’ document and use therapeutically
FBC + CRP + ferritinAnaemia causes fatigue, palpitations, and dyspnoea that worsen anxiety. CRP excludes inflammatory or infective cause. Ferritin β€” iron deficiency without anaemia causes fatigue and anxiety-like symptoms.Anaemia β†’ treat underlying cause; iron deficiency β†’ ferrous sulfate + cause investigation; raised CRP without source β†’ investigate systemic cause
HbA1c / fasting glucoseHypoglycaemia (in diabetics or hypoglycaemia unawareness) causes acute anxiety, tremor, and palpitations. New anxiety in a patient with diabetes risk factors warrants screening. Metformin causes B12 deficiency which worsens anxiety and depression.HbA1c β‰₯48 β†’ diabetes pathway alongside anxiety treatment; hypoglycaemia episodes β†’ urgent diabetes review; B12 if on metformin with low mood + anxiety
U&E + calcium + LFTsHypercalcaemia causes anxiety, depression, and fatigue. Uraemia (CKD) causes anxiety-like symptoms. LFT derangement may indicate alcohol excess. Not routine for every GAD patient β€” indicated in new-onset anxiety in older adult, prominent GI/neurological symptoms, or suspected alcohol dependence.Hypercalcaemia β†’ PTH + malignancy workup; significant LFT abnormality β†’ liver disease screen; renal impairment β†’ nephrology
24-hour urinary catecholamines or plasma metanephrines (specialist)Phaeochromocytoma presents with paroxysmal anxiety, hypertension, diaphoresis, and palpitations. Although rare, missing it is catastrophic. Indicated when: episodic hypertension >180/120 + classic triad, or anxiety not responding to standard treatment. Specialist-ordered only.Elevated catecholamines β†’ urgent endocrinology + CT adrenals; confirmed phaeochromocytoma β†’ surgical referral; anxiety treatment deferred until tumour resected
πŸŽ“ SCA Checkpoint β€” Step 4TasksGlobal Skills
Investigation communication that scores
"I'd like to ask you to complete this short questionnaire about your anxiety β€” it helps me understand how severe it is and choose the right level of support."
"I'm also going to check your thyroid function and do an ECG β€” not because I think something is seriously wrong, but because these are two tests that can cause symptoms like yours, and I want to reassure you completely once we have those results."
"I want to be honest with you: running lots of tests for every symptom isn't always the most helpful approach when anxiety is the cause β€” more tests tend to feed the worry rather than settle it."
Investigation deductions
  • Not using GAD-7 as a validated tool β€” clinical impression alone is not equivalent
  • Not using PHQ-9 β€” missing comorbid depression in 50–70% of cases
  • Ordering extensive investigation panel that reinforces health anxiety
  • Not ordering TSH in a patient with new anxiety + palpitations + weight change
πŸ”΄ Red
No GAD-7 or PHQ-9; no TSH in somatic anxiety presentation; orders extensive investigation panel reinforcing health anxiety; investigation plan not explained to patient.
🟠 Amber
GAD-7 mentioned but not scored; TSH ordered but rationale not explained; PHQ-9 not completed; investigations ordered but results not discussed in context of reassurance.
🟒 Green
GAD-7 scored and interpreted; PHQ-9 completed; TSH + ECG if clinically indicated with rationale explained; risk of over-investigation addressed explicitly if health anxiety present; results used therapeutically.
5
Step 5
Reaching a Diagnosis & DDx β€” Explained in Plain Language
β–²collapse
The diagnostic conversation in GAD has a dual purpose: giving the patient a valid, named diagnosis that explains their experience, and specifically addressing the somatic symptoms and fears that have been maintaining their distress. A patient who leaves without understanding the link between their anxiety and their physical symptoms will return for further investigation. "It's anxiety" said without elaboration is one of the most demoralising and unhelpful things a GP can say.
πŸ—£οΈ Explaining the Diagnosis in Plain Language β€” say something like this

"What I think is happening is that your brain's alarm system β€” the part designed to keep you safe from danger β€” has become overtuned. When it fires, your body prepares for danger: your heart rate increases, your breathing speeds up, your muscles tense, and your thinking narrows to scan for threats. That's why you get the palpitations, the chest tightness, the headaches, and the constant feeling that something terrible is about to happen. The difficulty is that this system keeps firing when there's no actual danger β€” it's triggered by uncertainty, by thoughts, by ordinary daily situations. That's generalised anxiety disorder: a very treatable condition where the brain's threat-detection system has become hypersensitive. It doesn't mean you're weak or 'mad' β€” it means your brain is doing what it was designed to do, just too much and too often."

πŸ’¬ Addressing the patient's own explanation β€” why it may not be the full picture

"I think there's something wrong with my heart β€” the palpitations feel so real."
"Your palpitations are absolutely real β€” I'm not suggesting you're imagining them. What I can tell you is that your heart examination and ECG are completely normal, and palpitations are one of the most common physical symptoms of anxiety. Anxiety directly activates your heart's accelerator β€” it's not a coincidence that your palpitations happen when you're stressed or worried. Once we treat the anxiety, most people find those palpitations disappear entirely."

"I just need to get a grip β€” I can't understand why I can't just stop worrying."
"I hear that a lot, and I want to gently push back on it. Anxiety isn't a failure of willpower β€” it's a biological process that happens below the level of conscious control. Telling yourself to stop worrying is like telling your heart to slow down by choosing to be calm. We have very effective treatments that work with the biology rather than against it. You haven't been able to 'just stop' because it's not that kind of problem."

A β€” Primary Care Diagnosis
GP diagnoses and manages

Generalised Anxiety Disorder (GAD) β€” Excessive, uncontrollable, multi-domain worry β‰₯6 months + β‰₯3 associated symptoms + significant impairment. GAD-7 β‰₯10 supports diagnosis. NICE CG113 / DSM-5 criteria.

Adjustment disorder with anxiety β€” Anxiety <6 months, clear precipitant, proportionate. Watchful waiting, psychoeducation, and social support often sufficient.

GAD with comorbid depression β€” PHQ-9 β‰₯10 alongside GAD-7 β‰₯10. SSRI addresses both; NHS Talking Therapies dual-pathway; close monitoring.

B β€” Related Anxiety Disorders β€” Differentiate and Manage Specifically
Different CBT approach needed

Panic Disorder

Discrete unexpected panic attacks + anticipatory worry about future attacks + avoidance. Interoceptive exposure CBT; SSRIs effective.

Social Anxiety Disorder

Anxiety specifically in social or performance situations; fear of negative evaluation. Distinct CBT pathway; SSRI effective.

Health Anxiety (Illness Anxiety Disorder)

Excessive worry about having a serious illness despite negative investigations; reassurance-seeking. Avoid over-investigation; CBT addresses threat appraisal.

C β€” Important Differentials β€” Do Not Miss
Exclude before diagnosing GAD

Hyperthyroidism

TSH <0.1 + free T4 elevated + anxiety + palpitations + weight loss β†’ urgent endocrinology + propranolol + carbimazole.

PTSD

Trauma history + hypervigilance + intrusive symptoms + avoidance β†’ EMDR or trauma-focused CBT; do not treat as GAD without PTSD screen (PCL-5 or PTSD-4).

Phaeochromocytoma / Cardiac Arrhythmia

Episodic hypertension + diaphoresis + palpitations / ECG arrhythmia β†’ urgent investigation; do not attribute to anxiety without excluding these.

πŸ“Š GAD Severity Classification β€” NICE CG113 Stepped Care
GAD-7 scoreSeverityNICE StepPrimary care management
GAD-7 0–4Minimal / noneStep 1 β€” IdentificationWatchful waiting; psychoeducation; lifestyle advice; review in 2–4 weeks if symptoms worsen
GAD-7 5–9Mild anxietyStep 2 β€” Low intensityGuided self-help (bibliotherapy, online CBT); psychoeducation; lifestyle; NHS Talking Therapies low-intensity referral
GAD-7 10–14Moderate anxietyStep 3 β€” High intensitySSRI (sertraline 50mg) + high-intensity CBT via NHS Talking Therapies; 2-week SSRI review; monthly monitoring; PHQ-9 serial
GAD-7 15–21Severe anxietyStep 3/4 β€” Specialist considerationSSRI + high-intensity CBT; consider SNRI if SSRI fails; specialist mental health referral; pregabalin second-line (specialist)
GAD-7 β‰₯10 + PHQ-9 β‰₯10Comorbid anxiety + depressionStep 3 β€” Dual pathwaySSRI addresses both; NHS Talking Therapies dual pathway; 2-week suicide review; monthly monitoring; PHQ-9 + GAD-7 at every contact
πŸŽ“ SCA Checkpoint β€” Step 5TasksRelating to OthersGlobal Skills
Diagnostic phrases that score
"What I think is happening is that your brain's alarm system has become overtuned β€” and it's those alarm signals that are causing the palpitations, the chest tightness, and the constant sense of dread."
"This is called generalised anxiety disorder β€” one of the most common and most treatable conditions we see. What you're experiencing has a name and an explanation."
"I want to be clear about what I've ruled out β€” your ECG and thyroid function are normal. This is not a heart problem or a thyroid problem β€” it's an anxiety problem, and anxiety is very treatable."
Diagnostic deductions
  • Saying "it's just anxiety" without an explanation β€” dismissive and clinically inadequate
  • Not distinguishing GAD from panic disorder, social anxiety, or PTSD
  • Not connecting physical symptoms (palpitations, headaches) to the anxiety diagnosis explicitly
  • Failing to address the patient's specific disease model (the heart fear must be addressed by name)
πŸ”΄ Red
No named diagnosis; "it's just anxiety" without explanation; does not connect physical symptoms to diagnosis; does not address heart fear; does not tell patient what has been excluded.
🟠 Amber
Correct diagnosis named but poorly explained; physical symptoms not linked to anxiety mechanism; organic exclusion not communicated; stigma not addressed; patient leaves without understanding the diagnosis.
🟒 Green
Named diagnosis with biological analogy (brain alarm system); physical symptoms explicitly linked to anxiety; organic causes excluded by name; stigma addressed (not weakness); prognosis positive; NICE step matched to GAD-7 score.
6
Step 6
If Referral Is Needed β€” What the GP Does Before & During
β–²collapse
GAD is managed largely in primary care or via NHS Talking Therapies. NHS Talking Therapies is not a "referral out" β€” it is an integrated primary care psychological therapy service. The GP's role after NHS Talking Therapies referral is to maintain the medication element, monitor response, and provide relational continuity. Specialist mental health referral (CMHT) is indicated only for complex, refractory, or high-risk presentations.
Condition / ScenarioUrgencyWhat GP does before referralWhat GP must NOT do
NHS Talking Therapies referral β€” all GAD presentations (Step 2 and above) Routine β€” self-referral or GP referral Explain NHS Talking Therapies: free NHS psychological therapy; no psychiatrist needed; includes guided self-help, CBT, counselling. Patient can self-refer directly. Explain waiting times vary β€” provide self-help resources in the meantime. Do NOT refer to NHS Talking Therapies and stop all contact β€” GP must continue monitoring while patient awaits NHS Talking Therapies. Do NOT present medication and therapy as either/or β€” they are complementary.
Active suicidal ideation (PHQ-9 item 9 positive with plan) Same-day β€” CRHT / mental health crisis Do not leave patient alone. Phone CRHT or mental health single point of access directly. Document risk assessment and action taken. Inform next of kin with patient consent if possible. Do NOT send a patient with active suicidal ideation home with a prescription alone. Do NOT book a routine 2-week follow-up as the sole response to active suicidal ideation.
Refractory GAD β€” failed 2 SSRIs at adequate dose and duration Routine β€” CMHT / specialist MH Document two adequate SSRI trials (sertraline 100mg for β‰₯12 weeks, then escitalopram or venlafaxine trial); document NHS Talking Therapies engagement and outcome; ensure comorbid depression, substance use, and personality disorder considered; review benzodiazepine use. Do NOT refer as "treatment failure" after a single SSRI trial at low dose for 4 weeks. Do NOT add pregabalin in primary care without specialist input. Do NOT continue benzodiazepines while awaiting CMHT.
Suspected PTSD (trauma history + hypervigilance + intrusions) Routine β€” NHS Talking Therapies trauma pathway / EMDR Screen with PCL-5 or PTSD-4; if positive β†’ refer to NHS Talking Therapies trauma pathway for EMDR or trauma-focused CBT; sertraline appropriate for PTSD-associated depression/anxiety. Do NOT treat PTSD as GAD β€” standard CBT without trauma focus is ineffective and potentially harmful. Do NOT explore trauma in detail in primary care without preparation and a safe environment.
GAD with benzodiazepine dependence Urgent β€” Drug and Alcohol Service Calculate current benzodiazepine dose; convert to equivalent diazepam dose; plan gradual withdrawal (10% reduction every 2–4 weeks β€” Ashton Manual approach); add SSRI to treat underlying GAD; refer to drug and alcohol services for complex cases. Do NOT abruptly stop benzodiazepines β€” risk of seizures if high-dose dependence. Do NOT continue to prescribe benzodiazepines long-term as substitute for active GAD management.
GAD in pregnancy or postpartum Urgent β€” perinatal mental health team within 2 weeks Refer urgently to perinatal mental health team; sertraline is the preferred SSRI in pregnancy (most safety data); avoid benzodiazepines in pregnancy; assess for postnatal depression alongside anxiety (Edinburgh scale). Do NOT withhold SSRI in severe anxiety in pregnancy β€” untreated severe anxiety is more harmful to the foetus than sertraline. Do NOT use paroxetine in the first trimester (cardiac defect risk).
Anxiety in child or adolescent (<18 years) Routine β€” CAMHS (if severe) or young person NHS Talking Therapies Complete GAD-7; screen for school avoidance; involve school counsellor or SENCO; parental psychoeducation; refer to young person NHS Talking Therapies for mild-moderate; CAMHS for severe, complex, or risky presentations. Do NOT prescribe SSRIs as first-line in under-18 without specialist input β€” psychological therapy is first-line per NICE CG113. Do NOT dismiss school avoidance as non-urgent.
πŸŽ“ SCA Checkpoint β€” Step 6TasksRelating to Others
Referral phrases that score
"NHS Talking Therapies is a free NHS service β€” you don't need to see a psychiatrist; it's a team of specially trained therapists who work with anxiety. The evidence for CBT is actually the most effective treatment we have for this condition."
"I'm going to refer you to NHS Talking Therapies, but I'm not handing over and disappearing β€” I'll continue to see you while you wait and while you're in therapy, particularly to manage the medication side of things."
Referral deductions
  • Referring to NHS Talking Therapies and implying no further GP involvement β€” patients feel abandoned
  • Not explaining what NHS Talking Therapies is β€” many patients assume it means seeing a psychiatrist
  • Prescribing pregabalin in primary care without CMHT input or adequate SSRI trial
  • Not referring pregnant patient with GAD to perinatal mental health team
πŸ”΄ Red
NHS Talking Therapies not mentioned; prescribes benzodiazepine as primary treatment; does not refer to CRHT for active suicidal ideation; adds pregabalin without specialist input.
🟠 Amber
NHS Talking Therapies mentioned but not explained; referral pathway correct but urgency wrong; does not maintain GP involvement after referral; medication and therapy presented as either/or.
🟒 Green
NHS Talking Therapies explained clearly as NHS therapy; GP continues involvement alongside NHS Talking Therapies; correct urgency for each pathway; benzodiazepine dependence addressed with structured withdrawal; CMHT threshold correctly identified.
7
Step 7
Management β€” Expectation Β· Goals Β· Lifestyle Β· Prescribing Β· Drug Cards Β· Psychosocial Β· Follow-Up Β· Safety-Netting
β–²collapse
GAD management follows the NICE CG113 (2023) stepped care model. Step 2 (mild GAD): psychoeducation, self-help, lifestyle optimisation, NHS Talking Therapies low-intensity referral. Step 3 (moderate-severe GAD): high-intensity CBT + SSRI β€” these are equally effective and complementary, not alternatives. Step 4: specialist review, SNRI, pregabalin consideration. The most common failure in primary care GAD management is offering one component (usually medication) without the other (usually psychology). Both together is significantly superior to either alone.
7A β€” Address the patient's expectation first: validate β†’ explain β†’ negotiate
🀝
Never dismiss the expectation β€” acknowledge it, share your reasoning, then agree a shared plan
1
Validate β€” name their expectation

The most common expectation in GAD is "something to calm me down" β€” often meaning benzodiazepines. This is entirely understandable and must be validated before it can be redirected. Immediately saying "I won't prescribe diazepam because it's addictive" shuts the conversation and damages the therapeutic relationship.

"I completely understand why you'd want something that takes the edge off quickly β€” when you're this anxious, you just want relief and you want it now. That makes complete sense."
2
Explain β€” share your clinical reasoning

Explain why the short-term appealing option (benzodiazepines) is less helpful than the longer-term approach, and why the evidence-based treatments (CBT + SSRI) work better. Use the brain alarm system analogy to explain the mechanism.

"The difficulty with something like diazepam is that it turns down the alarm temporarily, but it doesn't fix the reason it's overtuned β€” and over time, the alarm can actually become more sensitive. What CBT and the right medication do is retune the alarm, which is a more lasting solution."
3
Negotiate β€” offer something today

Never leave the patient with nothing. If SSRI is appropriate, start it today. Make the NHS Talking Therapies referral today. Provide written self-help resources. If a very short-term anxiolytic is truly necessary, a strict 2-week benzodiazepine course is negotiable β€” with clear agreement about limits.

"What I can offer you today: a start on the medication with the best evidence for this kind of anxiety β€” most people notice a difference within 2–4 weeks; a referral to NHS Talking Therapies for the talking therapy that works best for GAD; and some written resources for the meantime. Let's also agree a follow-up in 2 weeks."
Key principle: The patient who asks for a benzodiazepine deserves to have that expectation heard and validated before it is negotiated. A GP who immediately refuses without acknowledgement will lose the therapeutic relationship. The patient who feels heard is far more likely to accept the alternative plan.
7B β€” Why treatment matters: goals tailored to this patient
Treatment goals β€” shared with the patient
Reduce GAD-7 score by β‰₯50% from baseline Restore sleep quality and duration Return to avoided activities (driving, socialising, work) Reduce reassurance-seeking and checking behaviours Develop tolerance of uncertainty (CBT goal) Reduce physical anxiety symptoms (palpitations, tension, headaches) Prevent relapse with long-term self-management skills from CBT Named follow-up with serial GAD-7 and PHQ-9 monitoring
Motivational language β€” tailored to the patient
"CBT for GAD has around a 60–70% response rate β€” significantly better than medication alone. The skills you learn stay with you after treatment ends in a way medication can't provide. Most people who complete CBT say they feel more in control of their minds than they ever have."
"I know it's hard to imagine feeling different when anxiety has been this constant. But the research is genuinely optimistic for GAD β€” it responds well to treatment. Many people with your level of anxiety look back 6 months later and can't believe how different they feel."
7C β€” Non-medication management: mechanism + evidence + tailored advice
Lifestyle interventions have strong evidence in GAD and should be offered at every step of the care pathway. Caffeine reduction and exercise are the two lifestyle interventions with the most robust evidence base specifically for anxiety disorders. These are not alternatives to CBT or medication β€” they are the foundation that makes other treatments more effective.
β˜•
Caffeine Reduction
<200mg/day; switch to decaf after noon
Mechanism

Caffeine blocks adenosine receptors (the brain's natural calming system), increases cortisol, activates the HPA axis, and directly triggers anxiety, palpitations, and insomnia. Even moderate intake (2–3 cups/day) significantly worsens GAD symptoms via adenosine antagonism and catecholamine release.

Practical

Quantify intake across all sources: coffee, tea, cola, energy drinks, chocolate. Switch to decaffeinated versions after noon. Reduce gradually over 1–2 weeks to avoid withdrawal headaches. 200mg/day is a reasonable limit (about 2 cups of filter coffee).

Caffeine reduction alone reduces anxiety by 30–40% in high consumers within 2–4 weeks
πŸƒ
Aerobic Exercise
150 min/week moderate intensity
Mechanism

Regular aerobic exercise reduces amygdala reactivity, increases GABA and endorphin levels, normalises HPA axis cortisol, and improves sleep quality. A single session of moderate exercise produces acute anxiolytic effects lasting 4–6 hours.

Practical

Brisk walking, swimming, cycling, or running 30 minutes, 5 days/week. Social exercise (classes, sport) provides additional social support benefit. Morning exercise improves sleep quality. Yoga and Tai Chi have specific evidence for anxiety reduction via parasympathetic activation.

Exercise reduces GAD symptoms with effect size comparable to SSRIs in meta-analyses
😴
Sleep Optimisation
Consistent 7–9 hours; fixed wake time
Mechanism

Sleep deprivation amplifies amygdala reactivity to threat and reduces prefrontal cortex regulation of the fear response β€” making anxiety both more intense and harder to control. Anxiety and poor sleep form a bidirectional vicious cycle.

Practical

Fixed morning wake time (most important single sleep behaviour change); no screens 1 hour before bed; cool, dark, quiet room; no alcohol (disrupts REM sleep); if lying awake worrying for >20 minutes, get up and do a quiet activity. CBT-I (CBT for insomnia) when sleep is a primary problem.

Improving sleep quality reduces GAD severity significantly β€” treat sleep alongside anxiety, not after
🍷
Alcohol Reduction
AUDIT-C; <14 units/week; reduce evening use
Mechanism

Alcohol provides initial anxiolysis via GABA enhancement but causes significant rebound anxiety 4–6 hours later as GABA receptors downregulate. Regular evening drinking creates a morning anxiety cycle. Many patients with GAD use alcohol to self-medicate β€” this creates a maintenance cycle preventing SSRI effectiveness.

Practical

AUDIT-C at every anxiety consultation; brief intervention (FRAMES); advise alcohol-free days; reduce particularly before bed; connect alcohol reduction to anxiety improvement as a motivational frame.

Reducing alcohol to safe limits frequently resolves or significantly improves GAD without other intervention
🧘
Mindfulness and Relaxation
10–20 min daily; MBSR programme evidence-based
Mechanism

Mindfulness deactivates the default mode network (the brain's rumination circuit), reduces amygdala reactivity, and increases prefrontal regulation of the fear response. MBSR has RCT evidence for GAD with effect sizes comparable to active treatment.

Practical

Apps: Headspace (GAD-specific programme), Calm, Woebot (CBT-based chatbot). MBSR 8-week programme available via NHS Talking Therapies and NHS online. Progressive muscle relaxation effective for physical tension. Diaphragmatic breathing (4-7-8 technique or box breathing) for acute anxiety management.

MBSR reduces GAD severity comparably to cognitive therapy in systematic reviews
πŸ‘₯
Social Connection and Prescribing
Regular meaningful social contact; community activities
Mechanism

Social isolation is both a consequence of GAD avoidance and an independent maintaining factor. Meaningful social contact is the most powerful natural anxiolytic. Group CBT for anxiety provides both treatment and social exposure simultaneously.

Practical

Social prescribing link worker referral; community groups (MIND, anxiety support groups, exercise classes); group CBT via NHS Talking Therapies; volunteering; befriending services. Encourage gradual re-engagement with avoided social activities as behavioural activation.

Social prescribing improves mental health outcomes in primary care with low cost and no adverse effects
7D β€” Prescribing guide: NICE CG113 stepped care pharmacology
NICE CG113 (2023) first-line pharmacological treatment for moderate-severe GAD is an SSRI. Sertraline is the preferred first-line SSRI due to its pharmacokinetic profile, tolerability, and safety in cardiac disease. SNRIs (venlafaxine, duloxetine) are equally effective first-line alternatives. Pregabalin is second-line after two SSRI/SNRI failures β€” NICE moved it from first-line to second-line in 2019 due to misuse and dependence concerns. Benzodiazepines are not recommended for routine GAD β€” maximum 2 weeks in crisis only.
Step 1 β€” SSRI (Sertraline β€” First Choice)

Sertraline 50mg OD β€” take in the morning; titrate to 100mg at 4 weeks if inadequate response; maximum 200mg; trial duration β‰₯12 weeks at therapeutic dose before declaring failure.

  • Preferred over other SSRIs: lowest drug interaction profile and best cardiac safety
  • Always warn about initial anxiety worsening (first 1–2 weeks) β€” common and temporary
  • Onset of anxiolytic effect: 2–4 weeks; full effect at 6–12 weeks
  • Continue for minimum 12 months after remission β€” reduces relapse by 50%
2-week review MANDATORY after initiation β€” check tolerability and suicide risk in comorbid depression
Step 1 (Alternative) β€” SNRI (Venlafaxine or Duloxetine)

Venlafaxine XR 75mg OD (escalate to 150mg if needed) or Duloxetine 30mg OD (escalate to 60–120mg). Both first-line alternatives to SSRIs for GAD with similar efficacy.

  • Venlafaxine: preferred if pain comorbidity; warn about discontinuation syndrome
  • Duloxetine: good evidence in GAD + comorbid pain (fibromyalgia, neuropathic pain)
  • Blood pressure monitoring with venlafaxine above 150mg: noradrenergic effect raises BP
⚠ Venlafaxine: most severe discontinuation syndrome of all antidepressants β€” never stop abruptly; taper over β‰₯4 weeks
Step 2 β€” Pregabalin (Second-Line β€” Specialist Input Required)

Pregabalin 75mg BD (escalate to 150–300mg BD). Second-line after adequate trial of β‰₯2 SSRIs/SNRIs has failed. NICE CG113 (2023) requires specialist involvement before initiation.

  • Controlled drug (Schedule 3) β€” monitor for misuse; urine drug screen before initiation
  • Faster onset than SSRIs (days vs. weeks) β€” but limited to short-term use
  • Risk of dependence and misuse β€” do not prescribe to patients with substance use disorder without specialist input
⚠ Controlled drug Schedule 3 β€” document clinical justification; specialist input before prescribing in primary care
Benzodiazepines β€” For Crisis Use Only (Maximum 2 Weeks)
  • Not recommended for routine GAD management β€” NICE CG113
  • Acceptable (maximum 2 weeks): acute severe distress during SSRI initiation while awaiting onset; crisis situation
  • Diazepam 2–5mg TDS PRN β€” if prescribed, document indication clearly, fixed end date, and plan for SSRI to replace
  • Never in older adults β€” falls, cognitive impairment, paradoxical agitation
  • Benzodiazepine dependence: convert to equivalent diazepam; 10% reduction every 2–4 weeks; Ashton Manual protocol
Adjunctive Options β€” Buspirone, Hydroxyzine, Propranolol, Mirtazapine
  • Buspirone: anxiolytic without dependence; slow onset (2–4 weeks); useful if benzodiazepine-dependent; non-addictive
  • Hydroxyzine: rapid onset antihistamine anxiolytic; non-addictive; drowsiness is main side effect; max 50mg TDS
  • Propranolol 10–40mg PRN: reduces peripheral anxiety symptoms (palpitations, tremor); no central anxiolytic effect; useful for performance anxiety; avoid in asthma/COPD
  • Mirtazapine: useful in GAD with comorbid insomnia and poor appetite; sedating; appetite-stimulating; not first-line for GAD
βš™ Interactive Medication Chooser β€” tick the patient profile, options re-tier live against NICE / BNF
A live, topic-scoped version of the standalone Medication Chooser. The static selector and reference cards below are unchanged.
7E β€” Medication selection tool β€” choose patient characteristics for tailored recommendation

Select patient characteristics β€” GAD treatment recommendation appears below

Treatment recommendation
Select patient characteristics above to see tailored GAD treatment recommendation
7F β€” Drug reference cards: GAD pharmacotherapy
Sertraline (SSRI β€” First Choice)
Sertraline Β· Lustral Β· Generic
βœ“ Recommended
First-line50mg OD β†’ 100–200mg
βœ“ Prefer when
Moderate-severe GAD (GAD-7 β‰₯10) β€” first-line SSRI per NICE CG113
GAD with comorbid depression β€” treats both simultaneously
Cardiac disease β€” safest drug interaction profile of all SSRIs
Pregnancy β€” most safety data; preferred SSRI in pregnancy
βœ— Avoid if
MAOI within 14 days β€” serotonin syndrome risk
Pimozide co-prescription β€” QTc prolongation risk
Warfarin / anticoagulants β€” increased bleeding risk; monitor INR
⚠ Side effects
Initial (first 2 weeks): nausea, agitation, increased anxiety β€” warn proactively; usually resolves
Ongoing: sexual dysfunction, emotional blunting, insomnia or somnolence, weight change
Discontinuation: taper over β‰₯4 weeks; do not stop abruptly
πŸ”¬ Monitor
2 weeks: tolerability + suicide risk (mandatory NICE review)
4–6 weeks: GAD-7 response (target β‰₯50% reduction); if no improvement β†’ dose increase
12 weeks at therapeutic dose before declaring failure; continue 12 months after remission
πŸ’¬ Counselling

"This tablet takes 2–4 weeks to start working on the anxiety β€” in the first week or two you might feel slightly more anxious, which is normal and temporary. It doesn't change who you are; it reduces the biological over-activation. I want to see you in 2 weeks, and please contact us immediately if your thoughts become very dark."

The 2-week mandatory review after SSRI initiation is NICE CG113. SSRIs briefly increase energy before lifting mood β€” this is the highest suicide risk window. Missing this review in a patient with comorbid depression is a clinical governance failure and an SCA Task deduction.

Escitalopram (SSRI β€” Alternative)
Cipralex Β· Escitalopram Β· Generic
βœ“ Recommended
First-line alt10mg OD β†’ 20mg
βœ“ Prefer when
Sertraline failed or not tolerated β€” second SSRI option with different tolerability profile
Strong evidence base specifically for GAD in clinical trials (licensed indication)
Fewer drug interactions than citalopram or fluoxetine; well-tolerated profile
βœ— Avoid if
Known QTc prolongation β€” escitalopram has dose-dependent QTc effect; ECG before 20mg
Age >65 or hepatic impairment: maximum 10mg; QTc monitoring
⚠ Side effects
Similar to sertraline: initial nausea, insomnia, sexual dysfunction
QTc prolongation at higher doses β€” ECG at 20mg if cardiac risk
πŸ”¬ Monitor
2-week mandatory review; 4–6 week GAD-7 response
ECG if escalating to 20mg in patients with cardiac risk
πŸ’¬ Counselling

"This is a different version of the same class of medication β€” it works in a very similar way but sometimes suits different people better. The same rules apply: 2–4 weeks before you notice significant improvement, and I'll see you in 2 weeks to check how you're getting on."

Escitalopram has a specific licensed indication for GAD β€” making it, alongside sertraline and venlafaxine, one of the most evidence-supported pharmacological options. Fluoxetine is NOT a first-line choice for GAD (poor evidence base; long half-life; drug interactions).

Venlafaxine XR (SNRI)
Efexor XL Β· Venlafaxine XR Β· Generic
βœ“ Recommended
First-line75mg OD β†’ 150–225mg
βœ“ Prefer when
SSRI not tolerated or not effective β€” equally first-line per NICE
GAD with comorbid pain β€” noradrenergic component adds analgesic effect
GAD with severe fatigue β€” noradrenergic component improves energy
βœ— Avoid if
Uncontrolled hypertension β€” noradrenergic effect raises BP at >150mg
Cardiac arrhythmias β€” QTc effect; ECG monitoring at higher doses
⚠ Side effects
Nausea (very common initially β€” take with food)
BP elevation at >150mg β€” monitor BP 4-weekly when escalating
Most severe discontinuation syndrome of all antidepressants β€” taper over β‰₯4 weeks; never stop abruptly
πŸ”¬ Monitor
BP at 4 weeks and with every dose increase above 75mg
GAD-7 at 4–6 weeks and 12 weeks at therapeutic dose
πŸ’¬ Counselling

"Take this with food β€” nausea can be quite noticeable in the first couple of weeks. One very important thing: never stop this medication suddenly. If you want to stop, even after a course of treatment, we need to do it gradually β€” stopping abruptly can cause very unpleasant symptoms. Always come and talk to me first."

Venlafaxine discontinuation syndrome is the most important counselling point β€” it can be severe and distressing. Patients frequently stop suddenly when they feel better; the resulting syndrome is often misattributed to the anxiety returning. This counselling point is an SCA Task mark.

Pregabalin (Second-Line)
Lyrica Β· Generic pregabalin Β· Schedule 3 CD
βœ“ Recommended
Second-line75mg BD β†’ 150–300mg BD
βœ“ Prefer when
Two adequate SSRI/SNRI trials have failed β€” second-line per NICE CG113 (2023)
GAD with comorbid neuropathic pain β€” dual licence
Rapid onset needed (works within days) β€” but with specialist input only
βœ— Avoid if
History of substance misuse or drug-seeking behaviour β€” high misuse potential
Pregnancy β€” teratogenic risk; avoid particularly in first trimester
Elderly β€” falls risk; cognitive blunting; respiratory depression with opioids
⚠ Side effects
Dizziness and sedation (very common β€” warn to avoid driving initially)
Weight gain β€” significant and often treatment-limiting
Cognitive blunting β€” impaired concentration and memory
πŸ”¬ Monitor
GAD-7 at 4 weeks; response should be apparent within 1–2 weeks
Weight at baseline and 3-monthly
Controlled drug: quantity-limited prescriptions; urine drug screen at initiation
πŸ’¬ Counselling

"This medication works more quickly than the SSRI β€” you should notice a difference within a few days. The most common side effect is dizziness and feeling a bit 'spaced out' at first β€” that usually improves after a week or two. Don't drive until you know how it affects you. Because this is a controlled drug, we'll prescribe it in smaller quantities and review it regularly."

Prescribing pregabalin as first-line for GAD in primary care without specialist input or documentation of two SSRI failures is outside NICE CG113 guidance. Pregabalin is a Schedule 3 controlled drug β€” document clinical justification at every prescription.

Propranolol (Adjunct β€” Situational Anxiety)
Propranolol Β· Inderal Β· Beta-blockers
βœ“ Recommended
Adjunct10–40mg PRN
βœ“ Prefer when
Situational or performance anxiety (presentations, exams, interviews) β€” PRN use
Physical anxiety symptoms (palpitations, tremor, sweating) as prominent feature alongside SSRI
Adjunct to SSRI β€” does not replace central anxiolytic treatment
βœ— Avoid if
Asthma or COPD β€” bronchospasm risk; absolute contraindication
Heart block (2nd or 3rd degree) or severe bradycardia
Diabetes on insulin β€” masks hypoglycaemia warning signs
⚠ Side effects
Bradycardia, hypotension, cold extremities
Fatigue and exercise intolerance with regular use
Vivid dreams or nightmares (especially at night doses)
πŸ”¬ Monitor
Pulse and BP at initiation; resting HR should not drop below 55 bpm
PRN use only β€” avoid regular dosing for GAD; not a substitute for SSRI + CBT
πŸ’¬ Counselling

"Take this tablet about 30–45 minutes before the situation you find difficult β€” it won't stop you feeling anxious mentally, but it will stop your heart racing and your hands shaking, which often makes the whole experience feel much more manageable. It's not a long-term solution on its own, but it can be really useful while we work on the underlying anxiety with the other treatments."

Propranolol reduces peripheral anxiety symptoms but has no central anxiolytic effect β€” it does not treat the worry, only the physical manifestation. Prescribing it without also addressing the core anxiety (SSRI + CBT) is incomplete management.

Diazepam (Crisis / Withdrawal Only)
Diazepam Β· Valium Β· Schedule 4 CD
βœ“ Recommended
Crisis only2–5mg TDS; max 2 weeks
βœ“ Acceptable (limited) when
Acute severe distress while awaiting SSRI onset of effect β€” strictly ≀2 weeks only
Benzodiazepine withdrawal management β€” diazepam preferred for its long half-life (smoother withdrawal)
βœ— Avoid if
Routine GAD management β€” NICE CG113 explicitly does NOT recommend for long-term use
Older adults β€” falls, sedation, cognitive impairment, paradoxical agitation
History of alcohol or benzodiazepine dependence β€” high relapse risk
⚠ Side effects
Dependence develops within 2–4 weeks of regular use
Tolerance and rebound anxiety on stopping
Sedation, cognitive impairment, disinhibition
πŸ”¬ Monitor
Fixed 2-week end date documented at time of prescribing
Benzodiazepine withdrawal: 10% dose reduction every 2–4 weeks; never abrupt cessation
πŸ’¬ Counselling

"I'm prescribing this for a maximum of 2 weeks β€” I want to be very clear about that. It will help with the acute distress while we wait for the sertraline to work. Longer than 2 weeks, and there's a real risk of becoming dependent, which would create a new problem on top of the anxiety. We'll review at 2 weeks and this will be the last prescription unless there are exceptional circumstances."

Never prescribe diazepam for chronic GAD without a clear plan for cessation. If a patient requests "diazepam like before," acknowledge the request, explain the dependence risk, offer SSRI + CBT as the superior alternative, and if a short course is genuinely needed, prescribe with a fixed 2-week end date and document the clinical justification clearly.

7G β€” Psychosocial impact of the diagnosis: work, relationships, identity & daily life
πŸ«‚
Living with GAD β€” the invisible burden on daily life, relationships, and identity
GAD causes profound functional impairment across all domains of life. Unlike conditions with visible disability, GAD is entirely invisible to others, which adds a layer of shame and isolation. The patient who looks fine to colleagues while experiencing unbearable internal distress is a classic GAD presentation. Proactively discussing these impacts β€” and providing practical guidance β€” is both clinically necessary and a high-scoring SCA behaviour.
πŸ’Ό
Occupational Impact

GAD significantly impairs concentration, decision-making, and the ability to tolerate work uncertainty. Presenteeism (attending work while severely impaired) is more common than absenteeism in GAD.

Fit notes should be considered if severe GAD prevents effective work β€” "may be fit for work with adaptations" (flexible hours, reduced targets, remote working) is often more appropriate than full sick leave.

Employee Assistance Programmes (EAPs) often provide immediate CBT access β€” signpost proactively.

"How much is this anxiety affecting your work? Is it affecting your ability to concentrate or make decisions, or are there days when you can barely function?"
πŸš—
Driving and DVLA

Moderate-severe GAD can impair driving via poor concentration, hypervigilance, and avoidance of motorway or night driving. Patients should self-assess fitness to drive.

Benzodiazepines and pregabalin impair driving β€” patients must be counselled not to drive until their response to the medication is known.

DVLA notification is not routinely required for GAD β€” but if the patient believes their anxiety significantly impairs their driving, they should contact DVLA or their insurer.

"Some of the medications we're considering can affect your ability to drive safely, particularly when you first start them β€” please don't drive until you know how they affect you."
πŸ’‘
Relationships and Intimacy

GAD strains relationships through irritability, reassurance-seeking, avoidance, and emotional withdrawal. Partners often become inadvertent enablers β€” providing excessive reassurance that maintains the anxiety cycle.

Sexual dysfunction is common in GAD itself and worsened by SSRIs (delayed ejaculation, anorgasmia, reduced desire).

Couples or family therapy may be beneficial alongside individual CBT β€” relational dynamics maintaining anxiety need to be addressed.

"Has the anxiety affected your relationships β€” with your partner, your family? Do you find yourself needing a lot of reassurance from the people close to you?"
🧠
Identity and Self-Concept

Long-standing GAD often becomes entwined with identity β€” "I've always been a worrier" or "I'm just an anxious person." This self-labelling creates a barrier to treatment: patients may feel treating the anxiety is changing who they fundamentally are.

Reframing β€” "this isn't who you are, it's a treatable condition that's been happening to you" β€” is a powerful therapeutic intervention that shifts the relationship between patient and anxiety.

Recovery involves not just symptom reduction but identity reconstruction β€” supported by CBT and peer support.

"Some people who've been anxious for a long time start to feel like that's just 'who they are.' I want to gently offer a different perspective β€” this is something that's been happening to you, not something that defines you."
🌐
Social Life and Avoidance

Avoidance progressively restricts the patient's world β€” social events declined, activities abandoned, relationships withdrawn from. Each avoidance reduces anxiety short-term but maintains it long-term by preventing habituation.

Social prescribing β€” gentle re-engagement with community, peer groups, and activities β€” is both a treatment for avoidance and a source of social support that reduces anxiety biologically.

Group CBT for anxiety provides both the therapeutic intervention and the social exposure simultaneously.

"Has the anxiety caused you to start pulling back from things you used to do or people you used to see? Sometimes anxiety quietly shrinks our world over time without us fully noticing."
πŸ“‹
Benefits, Disability, and Legal Rights

Moderate-severe GAD that substantially affects normal daily activities for 12 months constitutes a disability under the Equality Act 2010 β€” employers must make reasonable adjustments.

For patients unable to work: Statutory Sick Pay, ESA, and PIP may be applicable. GP letters of support may be needed β€” provide factual, functional letters.

Social prescribing link workers can navigate the benefits system alongside clinical treatment.

"If the anxiety is making it very difficult to work, there may be things you're entitled to β€” both from your employer in terms of adjustments, and potentially financially. I can provide a supporting letter if that would help."
7H β€” Follow-up schedule
1
2 weeks β€” Mandatory SSRI review

If SSRI started: mandatory per NICE CG113. Assess: tolerability (nausea, agitation settling?), suicide risk in comorbid depression (PHQ-9 item 9), early signs of response. Review NHS Talking Therapies referral status. Adjust management if not tolerated.

Mandatory SSRI reviewSuicide risk if depressionNHS Talking Therapies referral status
2
4–6 weeks β€” Treatment response assessment

GAD-7 score (compare with baseline β€” target β‰₯50% reduction). PHQ-9 if depression. SSRI dose adequacy: if GAD-7 has not improved, increase dose (50β†’100mg sertraline). Side effects: particularly sexual dysfunction or emotional blunting β€” these may not be volunteered.

GAD-7 responsePHQ-9Dose review
3
3 months β€” CBT engagement and medication threshold

If no response to SSRI at 12 weeks at therapeutic dose β†’ switch SSRI or switch class (SSRI β†’ SNRI). CBT progress: has the patient started NHS Talking Therapies? Review technique and identify barriers. If GAD-7 improved but not to remission: continue current treatment; monthly review.

SSRI 12-week thresholdCBT engagementSwitch decision
4
6 months β€” Remission assessment and continuation planning

GAD-7 <5 = remission. If remission: plan minimum 12 months continuation of SSRI (reduces relapse by 50%). Review residual avoidance. If not in remission after 2 SSRIs: CMHT referral; consider SNRI or pregabalin with specialist input.

Remission assessmentContinuation planning
5
Annual β€” Relapse prevention and medication review

Annual review: GAD-7 and PHQ-9; medication continuation or planned tapering if stable for β‰₯12 months; discuss relapse warning signs; review self-management plan; social prescribing update; lifestyle review (caffeine, alcohol, exercise, sleep).

Annual GAD-7/PHQ-9Medication reviewRelapse prevention
7I β€” Monitoring: the SCALE mnemonic + treatment targets

Memory rule β€” GAD Monitoring: SCALE

Score (GAD-7 at every contact β€” target β‰₯50% reduction from baseline) Β· Comorbid depression (PHQ-9 β€” mandatory at every contact; item 9 suicide risk) Β· Adherence and side effects (sexual dysfunction, blunting β€” ask directly; venlafaxine BP monitoring) Β· Lifestyle (caffeine, alcohol, exercise, sleep β€” review at every contact) Β· Escalation threshold (no response at 12 weeks therapeutic dose β†’ switch; 2 SSRI failures β†’ CMHT referral)

TreatmentMonitoring parameterTimingAction threshold
Sertraline / SSRIGAD-7 + PHQ-9 + suicide risk + side effects + dose adequacy2 weeks (mandatory); 4–6 weeks; then monthly<50% GAD-7 at 6 weeks β†’ increase dose; <50% at 12 weeks at therapeutic dose β†’ switch agent; PHQ-9 item 9 β†’ same-day crisis assessment
Venlafaxine / SNRIBlood pressure + GAD-7 + discontinuation symptoms if reducingBP at 4 weeks and every dose increase; GAD-7 monthlyBP >150/90 on venlafaxine β†’ dose reduction or switch; taper only ≀37.5mg/month
PregabalinWeight + cognition + misuse markers + GAD-7Monthly for first 3 months; 3-monthly thereafterWeight gain >5kg β†’ address lifestyle; cognitive deterioration β†’ dose reduction; misuse signals β†’ reassess appropriateness
Diazepam (if prescribed)Dose, frequency, PRN use pattern; signs of dependenceWeekly review; 2-week hard stop documentedEscalating dose request β†’ structured withdrawal; any long-term use β†’ Ashton Manual reduction protocol
All treatmentsNHS Talking Therapies engagement; lifestyle changes; avoidance behaviour; quality of lifeEvery appointmentNot engaging with NHS Talking Therapies β†’ address barriers; persistent avoidance β†’ intensify CBT focus; deterioration despite treatment β†’ CMHT referral
Outcome measureTargetReview timing
GAD-7 responseβ‰₯50% reduction from baseline4–6 weeks; 12 weeks at therapeutic dose
GAD-7 remissionGAD-7 <56 months
PHQ-9 (comorbid depression)<10 (response); <5 (remission)Every contact; mandatory at 2-week SSRI review
SSRI treatment durationMinimum 12 months after remissionAnnual medication review
Avoidance behaviourProgressive re-engagement with avoided activitiesCBT review; every GP contact
Functional statusReturn to work / normal activities3-monthly; fit note review
7J β€” Safety-netting: exact phrases + medico-legal rationale

⚠ Three scenario-specific phrases β€” use these verbatim

πŸ”΄ Emergency β€” suicidal ideation (with SSRI or comorbid depression)
"I want to be very direct with you about something important. In the first couple of weeks on this medication β€” before it starts to lift the anxiety and the low mood β€” some people find their thoughts become darker. If at any point you have thoughts of harming yourself or ending your life, I need you to contact us the same day, call 999, or go to A&E. Please don't sit with those thoughts alone. Would you be comfortable telling me now β€” is that something you're experiencing at all?"
SSRIs increase energy before they lift mood β€” this creates a brief window of increased suicide risk in the first 2 weeks. NICE CG113 mandates a 2-week review specifically because of this. This safety-net is a mandatory component of every SSRI initiation in GAD + depression. The direct question at the end demonstrates active assessment rather than scripted warning β€” this is a Task mark.
πŸ’Š Medication β€” SSRI initial worsening of anxiety
"I want to warn you that in the first week or two on this medication, the anxiety may feel slightly worse before it gets better. This is temporary and it's a known effect β€” it's not the medication making you more anxious in a lasting way. If it feels unbearable or you feel you can't manage, please contact us and we can discuss whether a short course of something to help with the transition makes sense."
Initial anxiogenic effect of SSRIs is one of the most common reasons patients stop medication after 1–2 weeks, concluding it "made things worse." Pre-warning this effect dramatically improves adherence. This is both a medico-legal safety-net and a clinical effectiveness intervention β€” patients who expect this side effect persist with treatment.
🟠 Relapse β€” when to return early
"I'd like to see you in 2 weeks, and then monthly while we get the treatment established. Come back sooner if: the anxiety escalates significantly and becomes unmanageable; if new physical symptoms develop that you're worried about; or if the worry shifts into feelings of hopelessness or thoughts of harming yourself. Don't wait for your appointment if those things happen."
GAD has a relapsing course β€” patients need clear criteria to return early without feeling like a burden. Providing a specific list of return criteria (anxiety escalating, new somatic symptoms, hopelessness, self-harm thoughts) is both clinically appropriate and medico-legally protective. It also models appropriate health-seeking behaviour that interrupts the reassurance-seeking cycle.
2 weeks: Mandatory review if SSRI started β€” tolerability + suicide risk + NHS Talking Therapies status
4–6 weeks: GAD-7 response; dose adequacy; lifestyle review; CBT engagement
Same day / A&E: Active suicidal ideation; SSRI-related severe agitation; acute psychosis features
πŸŽ“ SCA Checkpoint β€” Step 7 (Final)TasksRelating to OthersGlobal Skills
Closing the consultation
"So β€” the plan: I'm starting you on sertraline 50mg, I'm referring you to NHS Talking Therapies for CBT, and I want to see you in 2 weeks to make sure it's sitting okay with you."
"In the first couple of weeks on the medication, the anxiety may feel slightly worse β€” this is temporary; please don't stop the tablet without talking to us first."
"If your thoughts become very dark at any point β€” if you feel like harming yourself β€” please contact us the same day or go to A&E."
"On the diazepam question β€” I hear you, and I understand why you want something that works quickly. Let me explain why I think there's a better option, and what I can offer you today instead."
"Is there anything we haven't covered, or anything else on your mind before we finish?"
Deductions β€” closing
  • Prescribing SSRI without arranging 2-week review and suicide safety-net
  • Prescribing benzodiazepine for chronic GAD without addressing dependence risk
  • Not explaining what NHS Talking Therapies is and why CBT is part of the plan
  • Not warning about initial SSRI anxiety worsening β€” leading to premature discontinuation
  • Telling patient to "just stop worrying" or dismissing the anxiety as stress
  • Not closing by checking if the patient has any questions
Tasks domain β€” full criteria
  • GAD-7 and PHQ-9 both used; scores interpreted and matched to NICE step
  • Organic causes excluded: TSH + ECG if clinically indicated
  • SSRI initiated at correct dose with dose escalation plan and duration explained
  • NHS Talking Therapies referral made alongside medication β€” not instead of
  • Mandatory 2-week SSRI review arranged; suicide safety-net given explicitly
Relating to Others β€” full criteria
  • ICE fully explored β€” disease model (heart fear), hidden concern, expectation for benzodiazepine
  • Biological explanation (brain alarm system analogy) given empathetically
  • Benzodiazepine expectation acknowledged before redirection β€” not dismissed outright
  • Physical symptoms explicitly linked to anxiety β€” not dismissed as "nothing wrong"
  • Stigma addressed: anxiety is biological, not weakness or character flaw
  • Closing question asked: "Is there anything else on your mind?"
πŸ”΄ Red β€” failing
No GAD-7 or PHQ-9; SSRI without 2-week review; prescribes benzodiazepine for chronic GAD; no NHS Talking Therapies referral; does not connect physical symptoms to anxiety; "just anxiety" without explanation; no closing question.
🟠 Amber β€” borderline
GAD-7 used but PHQ-9 omitted; 2-week review mentioned but not arranged; NHS Talking Therapies referenced not explained; benzodiazepine request not proactively addressed; initial SSRI worsening not pre-warned; ICE partially explored.
🟒 Green β€” passing
GAD-7 + PHQ-9 scored; NICE step matched; SSRI with initial worsening warning and suicide safety-net; NHS Talking Therapies explained and referred; organic causes excluded; benzodiazepine expectation acknowledged and negotiated; brain alarm system analogy; closing question asked.
Generalised Anxiety Disorder β€” SCA Consultation Scorecard
Based on the official SCA Consultation Tool Β· RAG self-assessment Β· Use after every practice consultation
0/ 33 pts
🌐
Global Skills
Structure, language, responsiveness
0/7
βœ“
Tasks
Clinical reasoning, diagnosis, management
0/15
🀝
Relating to Others
Communication, rapport, shared decision making
0/11
RAG Self-Assessment Guide
πŸ”΄ Red β€” not achieved
No GAD-7 or PHQ-9; SSRI without 2-week review; prescribes benzodiazepine for chronic GAD; no NHS Talking Therapies referral; "just anxiety" without explanation; does not address ICE; misses organic cause; no suicide safety-net.
🟠 Amber β€” partially achieved
GAD-7 used but PHQ-9 omitted; 2-week review mentioned not arranged; NHS Talking Therapies referenced not explained; benzodiazepine request not proactively addressed; initial SSRI worsening not warned; ICE partially covered.
🟒 Green β€” fully achieved
GAD-7 + PHQ-9 scored; NICE step matched; organic excluded; SSRI with initial warning + suicide safety-net; NHS Talking Therapies explained + referred; benzodiazepine expectation acknowledged and negotiated; biological explanation; closing question asked.
011172533
Fail
Borderline
Pass
Strong pass
πŸ“‹
Complete the checklist above to see your score interpretation and feedback
"I've been struggling for a while β€” my nerves, really. I know it sounds daft but I can't stop worrying about everything. I've been to A&E twice thinking it was my heart, but they said it was fine. I was hoping you might be able to give me something to help calm me down."
Who you are

Sarah Chen, 36 years old, secondary school teacher. Has been experiencing persistent, uncontrollable worry for about 9 months β€” about her job performance, her children's health, finances, relationships, and the state of the world. Wakes at 3 am with racing thoughts most nights. Has started avoiding motorway driving and declining social invitations. A&E twice with palpitations and chest tightness β€” both times cardiac causes were excluded. Feels embarrassed and believes she "should be able to control it." Drinks 4–5 cups of coffee per day and about 12–14 units of alcohol per week (wine in the evenings to "unwind"). PHQ-9 score: 9 (mild depression but below active treatment threshold). GAD-7 score when administered: 14 (moderate-severe).

Hidden agenda

Sarah is convinced something is wrong with her heart β€” she does not believe the A&E discharge was thorough enough. She secretly hopes for a cardiology referral, or at least a repeat ECG. The real fear underneath is not just cardiac disease β€” she worries she is "going mad," that she will lose control, and that her family will see her as unable to cope. She will not disclose this fear unless directly asked. She is also hoping for diazepam β€” a friend takes it and "it works immediately." She feels desperate enough to ask despite having heard it can be addictive.

Symptoms if asked directly
  • Worry: multi-domain; cannot stop once it starts; "a radio that won't turn off"
  • Duration: 9 months without a significant break
  • Physical: palpitations, chest tightness, daily tension headaches, muscle tension, fatigue
  • Sleep: wakes at 3 am approximately 4–5 nights/week; lies awake 1–2 hours with racing thoughts
  • GAD-7 score: 14 (moderate-severe); PHQ-9 score: 9 (sub-threshold depression)
  • No current suicidal ideation β€” PHQ-9 item 9 = 0
  • Avoidance: motorway driving, large social gatherings, has stopped yoga class
  • No weight loss, no heat intolerance, no thyroid symptoms
  • Caffeine: 4–5 cups filter coffee/day plus 2 diet colas; no reduction attempted
  • Alcohol: 12–14 units/week; mostly wine after 9 pm "to help me wind down"
Lifestyle + bonus details
  • Teaching very stressful β€” feels on verge of burnout; OFSTED inspection pending
  • Two children (ages 6 and 9) β€” worries excessively about them
  • Has never had CBT; heard of "talking therapy" but fears it won't work for her
  • Bonus detail (if doctor asks about caffeine): admits she drinks a lot of coffee but genuinely did not know it could worsen anxiety β€” very receptive to this information
  • Bonus detail (if doctor asks about evening alcohol): drinks "to relax" and has not connected it to the 3 am wakening β€” this is a significant therapeutic insight if the doctor makes the connection for her
"Look β€” I know you probably think I'm just stressed. But these palpitations feel so real. Can you refer me to a cardiologist? And what about something like diazepam? My friend takes it and it works straight away. I just need to get through the next few weeks until the OFSTED inspection is over."

Resolution: Sarah will accept the plan if the doctor: (1) directly acknowledges and addresses her cardiac fear by name β€” not obliquely; (2) explains the biological basis of anxiety and explicitly links her palpitations and chest tightness to the anxiety mechanism; (3) acknowledges the diazepam request empathetically before redirecting, rather than immediately refusing; (4) offers sertraline with a clear explanation including the initial worsening; (5) refers to NHS Talking Therapies and explains what CBT involves; (6) makes the connection between her caffeine intake and her anxiety symptoms β€” she genuinely does not know this link; (7) explores the evening alcohol as a 3 am wakefulness driver; (8) arranges a named 2-week review appointment; (9) gives her permission to return sooner if things escalate.

πŸ₯
Clinic Quick Reference
Generalised Anxiety Disorder β€” Clinical Decision Framework
NICE CG113 Β· CKS 2024 Β· NHS Talking Therapies Stepped Care
β–Όexpand
🚦 1 β€” Triage System
Patient presents with anxiety / worry / nervousness β†’ GAD-7 + PHQ-9 + organic screen (TSH, ECG) + red flag assessment
↓
πŸ”΄ Emergency
  • Active suicidal ideation with plan β†’ same-day CRHT
  • Phaeochromocytoma (episodic HTN >180/120 + diaphoresis) β†’ 999
  • Arrhythmia with haemodynamic compromise β†’ 999
  • Acute psychosis with anxiety features β†’ crisis team
  • Severe self-neglect / unable to care for dependants β†’ same-day psychiatric
999 / same-day crisis referral
🟠 Urgent β€” 24–72 hours
  • PHQ-9 β‰₯15 with ideation (no plan) β†’ CRHT contact same day
  • New anxiety in >50 without precipitant β†’ urgent bloods + ECG
  • Palpitations + syncope β†’ ECG same day + Holter
  • Benzodiazepine dependence needing withdrawal β†’ weekly GP review
  • GAD + severe depression β†’ SSRI within days; 2-week review
Urgent investigation / 2-week review
🟒 Routine β€” NICE stepped care
  • GAD-7 5–9 (mild) β†’ Step 2: self-help + NHS Talking Therapies low-intensity
  • GAD-7 β‰₯10 (moderate) β†’ Step 3: SSRI + CBT via NHS Talking Therapies
  • Step 3 failure β†’ Step 4: SNRI / CMHT / pregabalin (specialist)
  • All presentations: lifestyle (caffeine, alcohol, exercise, sleep)
NICE stepped care + NHS Talking Therapies referral
πŸ”¬ 2 β€” Diagnostic Pathway
GAD Diagnosis β€” NICE CG113 / DSM-5 Criteria
βœ… Duration: β‰₯6 months of excessive, uncontrollable worry
βœ… Multi-domain: Worry spans multiple life domains
βœ… Uncontrollable: Patient cannot stop or redirect worry voluntarily
βœ… Physical symptoms: β‰₯3 of: restlessness, fatigue, concentration, irritability, muscle tension, sleep disturbance
βœ… Impairment: Clinically significant distress or functional impairment
Exclude: hyperthyroidism, cardiac arrhythmia, substance use, PTSD, OCD, panic disorder, social anxiety
Investigations β€” Targeted
βœ… ALL presentations: GAD-7 (severity + NICE step); PHQ-9 (comorbid depression)
βœ… Somatic symptoms (palpitations, weight change): TSH + ECG
⚠ Episodic HTN + diaphoresis: 24h urinary catecholamines (phaeochromocytoma)
⚠ New anxiety >50 + systemic symptoms: FBC, LFTs, calcium, glucose
❌ Health anxiety: Avoid extensive investigation cascade β€” reinforces health anxiety
πŸ“Š 3 β€” Key Numbers
GAD-7 β‰₯10
Moderate-severe GAD β€” active treatment (SSRI + CBT)
6 months
Minimum duration for GAD diagnosis
2 weeks
Mandatory SSRI review (NICE CG113)
12 weeks
Adequate SSRI trial duration before declaring failure
12 months
Minimum SSRI continuation after remission (50% relapse reduction)
Sertraline
First-line SSRI for GAD (NICE CG113, 2023)
≀2 weeks
Maximum benzodiazepine duration in any anxiety
60–70%
CBT response rate in GAD
50–70%
GAD patients with comorbid depression β€” PHQ-9 mandatory
Pregabalin
Second-line only β€” after β‰₯2 SSRI/SNRI failures; Schedule 3 CD
β‰₯50%
GAD-7 reduction = treatment response target at 12 weeks
NHS Talking Therapies
Self-referral available β€” no GP referral required in most areas
πŸ’Š 4 β€” Medication Decision & Choice
NICE CG113 Prescribing Ladder
Step 1 (First-line): Sertraline 50mg OD (β†’100–200mg). Safest drug interaction profile. First-line for GAD and GAD + depression
Step 1 (Alternative): Escitalopram 10mg (β†’20mg) or Venlafaxine XR 75mg (β†’150mg). Both have specific GAD licence. Venlafaxine: never stop abruptly
Step 2 (Second-line): Pregabalin 75mg BD (β†’300mg BD). After β‰₯2 SSRI failures. Specialist involvement. Schedule 3 CD
Not recommended (chronic GAD): Benzodiazepines β€” max 2 weeks acute crisis only; SSRI + CBT are superior long-term
Comorbidity Drug Choice
GAD + depression: Sertraline 50mg (treats both); NHS Talking Therapies dual pathway; 2-week suicide review
GAD + cardiac disease: Sertraline (safest SSRI in IHD/arrhythmia); ECG monitoring
GAD + chronic pain: Duloxetine or venlafaxine (dual anxiety + pain benefit)
GAD + insomnia + poor appetite: Mirtazapine 15mg nocte (sedating + appetite-stimulating)
Performance anxiety only: Propranolol 10–40mg PRN (not for chronic GAD)
GAD in pregnancy: Sertraline (most safety data); refer perinatal MH team urgently
⚠ 5 β€” Safety Netting & Follow-Up
πŸ”΄ Emergency β€” suicidal ideation with SSRI / comorbid depression
"If your thoughts become very dark β€” if you think about harming yourself β€” contact us the same day, call 999, or go to A&E. Don't wait for your appointment."
πŸ’Š SSRI initiation β€” initial anxiety worsening
"In the first 1–2 weeks, the anxiety may feel slightly worse before it improves β€” this is normal and temporary. Don't stop without speaking to us first."
🟠 Relapse β€” when to return early
"Return sooner if: anxiety escalates and becomes unmanageable; new physical symptoms develop; thoughts become hopeless or dark; benzodiazepines become daily rather than PRN."
Follow-up timeline
1
2 weeks (mandatory if SSRI): Tolerability + suicide risk + NHS Talking Therapies contact status
2
4–6 weeks: GAD-7 response; PHQ-9; dose adequacy; lifestyle changes
3
3 months: 12-week SSRI threshold; switch decision if no response; CBT engagement
4
6 months: Remission assessment (GAD-7 <5); 12-month continuation plan
5
Annual: GAD-7 + PHQ-9; relapse prevention; medication review; lifestyle
πŸ“Œ 2-week SSRI review is NICE mandatory β€” cannot be omitted when starting SSRI in GAD + depression
πŸ”¬ 6 β€” Monitoring & Red Flags
TreatmentMonitorTimingAction threshold
Sertraline / SSRIGAD-7 + PHQ-9 + suicide risk + side effects2 weeks (mandatory); 4–6 weeks; monthly<50% GAD-7 at 6 weeks β†’ increase dose; <50% at 12 weeks β†’ switch; PHQ-9 item 9 β†’ crisis same day
VenlafaxineBlood pressure + GAD-7 + discontinuation symptomsBP every dose increase; GAD-7 monthlyBP >150/90 β†’ dose reduction; never stop abruptly β€” taper over β‰₯4 weeks minimum
PregabalinWeight + cognition + misuse + GAD-7Monthly (first 3 months); 3-monthlyWeight gain >5kg β†’ lifestyle intervention; cognitive decline β†’ dose reduction or switch
DiazepamDose escalation; frequency; dependency signsWeekly; 2-week hard stopAny ongoing use beyond 2 weeks β†’ structured withdrawal (Ashton protocol)
🚨 Red flags: Active suicidal ideation; episodic hypertension + diaphoresis (phaeochromocytoma); palpitations + syncope (arrhythmia); new anxiety >50 without precipitant; focal neurological symptoms; rapid weight loss + anxiety
πŸ›‘οΈ Safeguarding: Anxiety sustained by domestic abuse or coercive control; parent with severe GAD unable to meet children's needs; social isolation + hopelessness + alcohol + GAD = significant suicide risk; financial abuse causing anxiety
πŸŽ“
SCA Exam Quick Reference
SCA Consultation Blueprint
Tasks Β· Relating to Others Β· Global Skills Β· RAG guide
β–Όexpand
πŸ• 12-Minute Consultation Flow β€” with Domain Scoring
0–2 min
Open + Worry Characterisation
"Tell me about the worry in your own words β€” what's it been like for you?"
Use case card info first β€” do not re-ask documented duration. Open broadly and let the narrative emerge. Allow 60–90 seconds of uninterrupted account.
In the first 2 minutes: establish multi-domain nature of worry; assess controllability ("can you choose to stop it?"); get a sense of duration. These three questions classify the anxiety type.
Global SkillsRelating to Others
βœ— Starting with targeted symptom checklist Β· βœ— Re-asking documented facts Β· βœ— No open question Β· βœ— Jumping to "are you depressed?"
2–5 min
GAD-7 + PHQ-9 + ICE
"I'd like to ask you to fill in two short questionnaires β€” one about your anxiety, one about your mood. They help me be precise about the level of support you need."
GAD-7 AND PHQ-9 both mandatory. Administer, score, and use the scores to guide treatment. Then ICE: ideas (disease model), concerns (heart fear), expectations (diazepam request).
Heart fear is almost always the hidden concern in a patient with palpitations β€” probe for it directly: "Is there anything specific you've been worried this might be?"
TasksRelating to Others
βœ— GAD-7 but no PHQ-9 Β· βœ— ICE not explored Β· βœ— Heart fear not proactively asked Β· βœ— Substance use not reviewed
5–7 min
Examination + Organic Exclusion
"I'd like to check your pulse, blood pressure, and take a quick look at your neck β€” I want to be thorough and also give you concrete reassurance."
Pulse, BP, thyroid examination, cardiovascular auscultation. Communicate findings explicitly: "Your heart is completely regular, your pulse is normal, your thyroid feels fine β€” I can confidently say this is not your heart."
TasksGlobal Skills
βœ— No examination Β· βœ— Examination without communicating findings Β· βœ— Normal findings not used for reassurance Β· βœ— TSH and ECG not mentioned
7–10 min
Diagnosis + Benzodiazepine Negotiation
"What I think is happening is that your brain's alarm system has become overtuned β€” and that's what's causing the palpitations and the chest tightness."
Biological explanation (brain alarm system); physical symptoms linked to anxiety; organic causes excluded explicitly; stigma addressed. Connect caffeine intake to anxiety β€” she genuinely does not know this link.
Benzodiazepine request: "I completely understand why you'd want something that works immediately β€” let me explain why I think there's a better option." Validate before redirecting.
TasksRelating to Others
βœ— "It's just anxiety" without explanation Β· βœ— Dismissing benzodiazepine without acknowledgement Β· βœ— Cardiac fear not addressed by name Β· βœ— Caffeine link not made
10–12 min
SSRI + NHS Talking Therapies + Safety-Net + Close
"I'm starting you on sertraline β€” it may make the anxiety slightly worse at first, which is normal. I'm also referring you to NHS Talking Therapies for CBT. I need to see you in 2 weeks."
SSRI: initial worsening warning; 2-week review mandatory. NHS Talking Therapies: explain as NHS therapy (not psychiatry). Suicide safety-net if PHQ-9 elevated. Closing question to patient.
TasksRelating to OthersGlobal Skills
βœ— SSRI without initial warning Β· βœ— No 2-week review Β· βœ— NHS Talking Therapies not explained Β· βœ— No closing question Β· βœ— Alcohol/caffeine link not made
πŸ”΄πŸŸ πŸŸ’ RAG Scoring β€” All 3 Domains
Tasks Domain
🟒
GAD-7 + PHQ-9 both scored; organic excluded (TSH/ECG); SSRI with initial warning and 2-week review; NHS Talking Therapies referred and explained; suicide safety-net; lifestyle reviewed; benzodiazepine risk addressed
🟠
GAD-7 but no PHQ-9; 2-week review mentioned not arranged; NHS Talking Therapies referenced not explained; initial SSRI warning not given; benzodiazepine not proactively addressed; organic exclusion incomplete
πŸ”΄
No GAD-7 or PHQ-9; SSRI without review; prescribes benzodiazepine for chronic GAD; no NHS Talking Therapies; misses organic cause; no suicide safety-net
Relating to Others
🟒
ICE all three; cardiac fear named and addressed; biological explanation; stigma addressed; benzodiazepine acknowledged before redirected; physical symptoms linked to anxiety; shared decision making; closing question
🟠
ICE partially explored; cardiac fear not proactively raised; biological explanation vague; benzodiazepine refused without acknowledgement; physical symptoms not linked; no closing question
πŸ”΄
No ICE; cardiac fear dismissed; "it's just anxiety"; benzodiazepine immediately refused; no empathy; no shared decision making; patient leaves without understanding diagnosis
Global Skills
🟒
Open question; plain language; GAD-7/PHQ-9 signposted; examination communicated and used therapeutically; summary with SSRI + NHS Talking Therapies + follow-up; closing question; pacing appropriate for anxious patient
🟠
Targeted questions first; jargon without explanation; examination not communicated; summary incomplete; no closing question
πŸ”΄
No open question; dismissive or interrogative tone; no validated tools; no examination communicated; no summary; rushed consultation; patient not heard
πŸ’¬ Key Phrases β€” ICE, Diagnosis & Plan
Ideas β€” elicit disease model
"When the palpitations happen and the worry kicks in, what goes through your mind about what might be causing them?"
Concerns β€” cardiac fear (name it)
"I want to be direct β€” your heart examination is completely normal. I can confidently say this is not a heart problem. The palpitations are being caused by the anxiety."
Benzodiazepine β€” validate first
"I completely understand why you'd want something that works immediately β€” when you're this anxious, you just want relief. Let me explain why I think there's a better option."
Brain alarm analogy
"Your brain's alarm system has become overtuned β€” it keeps firing when there's no real danger. The palpitations, the tightness, the constant dread β€” that's the alarm system, not your heart."
SSRI initial worsening β€” pre-warn
"In the first week or two, the anxiety may feel slightly worse before it improves β€” this is normal and temporary. Don't stop without talking to us first."
Suicide safety-net (if PHQ-9 elevated)
"If at any point your thoughts become very dark, please contact us the same day or go to A&E. Don't sit with those thoughts alone."
🚫 9 Danger Zones β€” Instant Deductions
βœ—
Prescribing benzodiazepine for chronic GAD as primary treatment→ NICE CG113 explicitly does not recommend for chronic GAD; max 2 weeks crisis only; SSRI + CBT superior long-term
βœ—
SSRI without 2-week review and suicide safety-net→ NICE mandatory; SSRIs increase energy before mood — brief suicide risk window; failure is clinical governance breach
βœ—
Not using GAD-7 or PHQ-9β†’ Clinical impression alone is insufficient; validated tools are required for NICE-compliant management and are Task marks
βœ—
"It's just anxiety" without biological explanation→ This phrase dismisses the patient's experience; always provide the brain alarm system analogy or equivalent explanation
βœ—
Not excluding organic cause in new anxiety with palpitations→ TSH and ECG mandatory when somatic symptoms present; hyperthyroidism and arrhythmia are common mimics that change management entirely
βœ—
Dismissing benzodiazepine request without acknowledgement→ Must validate the expectation before redirecting; immediate refusal damages therapeutic alliance and is a Relating to Others deduction
βœ—
Not warning about SSRI initial anxiety worsening→ Most common reason for premature SSRI discontinuation; pre-warning dramatically improves adherence and is a Task mark
βœ—
Prescribing pregabalin as first-line in primary careβ†’ Second-line only per NICE CG113 (2023); requires β‰₯2 SSRI failures; specialist involvement; Schedule 3 CD β€” document justification
βœ—
Referring to NHS Talking Therapies and stopping all GP contact→ GP must continue monitoring (medication, risk, GAD-7) while patient awaits and receives NHS Talking Therapies; referral is not handover of care
πŸ’Š Drug Quick-Pick by Scenario
Moderate-severe GAD (GAD-7 β‰₯10) β€” first treatment
β†’Sertraline 50mg OD + NHS Talking Therapies referral
2-week mandatory review. Initial anxiety worsening pre-warned. 12 months after remission. Suicide safety-net if PHQ-9 elevated.
GAD + cardiac disease (IHD, arrhythmia)
β†’Sertraline (safest SSRI in cardiac disease)
Lowest drug interaction profile. Avoid TCAs. ECG monitoring. Propranolol adjunct for palpitations if needed.
GAD + chronic pain (fibromyalgia, neuropathy)
β†’Duloxetine 30β†’60mg or Venlafaxine 75mg
SNRI dual anxiolytic + analgesic benefit. Venlafaxine: monitor BP above 150mg. Never stop abruptly β€” taper over β‰₯4 weeks.
Situational / performance anxiety only
β†’Propranolol 10–40mg PRN (30–45 min before)
Peripheral symptoms only (palpitations, tremor). No central anxiolytic effect. Avoid in asthma/COPD. Adjunct to SSRI + CBT, not replacement.
GAD with benzodiazepine dependence
β†’Diazepam equivalent dose β†’ 10% taper every 2–4 weeks
Add sertraline alongside taper. Drug and alcohol service for complex cases. Never stop benzodiazepines abruptly β€” seizure risk.
Refractory GAD β€” failed β‰₯2 SSRIs at therapeutic dose
β†’Pregabalin 75mg BD (specialist input) + CMHT referral
Schedule 3 CD β€” document 2 SSRI failures. Weight gain, sedation, cognitive blunting common. Do not prescribe without specialist involvement.
β›” Never do: benzodiazepine for chronic GAD (max 2 weeks crisis only) | SSRI without 2-week review | pregabalin first-line in primary care without 2 SSRI failures | "it's just anxiety" without biological explanation | NHS Talking Therapies referral without continued GP involvement | venlafaxine stopped abruptly
Reviewed: July 2026 Β· citations verified against current NICE / UK guidance